Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
22,100 | 2023-10-27 00:00:00 UTC | Why AbbVie Stock Fell Today | ABBV | https://www.nasdaq.com/articles/why-abbvie-stock-fell-today | null | null | Shares of AbbVie (NYSE: ABBV) were down 5.4% as of 2:00 p.m. ET Friday, even after the pharmaceuticals giant announced slightly better-than-expected quarterly results and raised its full-year outlook.
For its third-quarter 2023, AbbVie's revenue declined 6% year over year (down 5.8% at constant currency) to $13.93 bill... | Finally, AbbVie modestly raised its quarterly cash dividend by $0.07 per share to $1.55 (payable on Feb. 15, 2024, to shareholders of record as of Jan. 16, 2024). Or maybe traders are lamenting the combination of the not-so-shocking decline in Humira sales, coupled with underwhelming results from AbbVie's oncology and ... | For its third-quarter 2023, AbbVie's revenue declined 6% year over year (down 5.8% at constant currency) to $13.93 billion, translating to a 19.4% drop in adjusted (non-GAAP) earnings to $2.95 per share. Double-digit gains for AbbVie's non-Humira growth platform AbbVie Chairman and CEO Richard Gonzalez called it "anoth... | Double-digit gains for AbbVie's non-Humira growth platform AbbVie Chairman and CEO Richard Gonzalez called it "another quarter of outstanding results driven by accelerating performance across our non-Humira growth platform, which is demonstrating double-digit growth." Meanwhile, revenue from AbbVie's oncology portfolio... | Meanwhile, revenue from AbbVie's oncology portfolio dropped 8.4% to $1.512 billion, and aesthetics portfolio sales -- including its cosmetic Botox sales -- dropped 4.7% to $1.239 billion. AbbVie is raising its guidance and dividend Looking ahead to its full-year 2023 outlook, AbbVie now expects adjusted earnings per sh... |
22,101 | 2023-10-27 00:00:00 UTC | AbbVie Enters Oversold Territory | ABBV | https://www.nasdaq.com/articles/abbvie-enters-oversold-territory-2 | null | null | The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. AbbVie Inc (Symbol: ABBV) presently has an... | A bullish investor could look at ABBV's 27.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. AbbVie Inc (Symbol: ABBV) presently has an excellent rank, in the top 25% of the coverage universe, which sugges... | In the case of AbbVie Inc, the RSI reading has hit 27.1 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 40.5. Indeed, ABBV's recent annualized dividend of 5.92/share (currently paid in quarterly installments) works out to an annual yield of 4.08% based upon t... | In the case of AbbVie Inc, the RSI reading has hit 27.1 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 40.5. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABBV is its dividend history. AbbVie Inc (Sym... | AbbVie Inc (Symbol: ABBV) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. Indeed, ABBV's recent annualized dividend of 5.92/share (currently paid in quarterly installments) works out to an ann... |
22,102 | 2023-10-27 00:00:00 UTC | IWY, TSLA, LLY, ABBV: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/iwy-tsla-lly-abbv%3A-etf-inflow-alert | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Top 200 Growth ETF (Symbol: IWY) where we have detected an approximate $111.8 million dollar inflow -- that's a 1.7% increase week over week in outstanding units (from 45,150... | Among the largest underlying components of IWY, in trading today Tesla Inc (Symbol: TSLA) is up about 1.4%, Eli Lilly (Symbol: LLY) is down about 0.5%, and AbbVie Inc (Symbol: ABBV) is lower by about 4.4%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate... | Among the largest underlying components of IWY, in trading today Tesla Inc (Symbol: TSLA) is up about 1.4%, Eli Lilly (Symbol: LLY) is down about 0.5%, and AbbVie Inc (Symbol: ABBV) is lower by about 4.4%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price performanc... | Among the largest underlying components of IWY, in trading today Tesla Inc (Symbol: TSLA) is up about 1.4%, Eli Lilly (Symbol: LLY) is down about 0.5%, and AbbVie Inc (Symbol: ABBV) is lower by about 4.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one ... | Among the largest underlying components of IWY, in trading today Tesla Inc (Symbol: TSLA) is up about 1.4%, Eli Lilly (Symbol: LLY) is down about 0.5%, and AbbVie Inc (Symbol: ABBV) is lower by about 4.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one ... |
22,103 | 2023-10-26 00:00:00 UTC | Pre-Market Earnings Report for October 27, 2023 : XOM, CVX, ABBV, SNY, AON, CHTR, CL, PSX, IMO, XEL, LYB, TROW | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-october-27-2023-%3A-xom-cvx-abbv-sny-aon-chtr-cl-psx-imo-xel | null | null | The following companies are expected to report earnings prior to market open on 10/27/2023. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation (XOM)is reporting for the quarter ending September 30, 2023. The oil company's consensus earnings per share forecast from the 9 ... | AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2023. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABBV is 13.19 vs. an industry ratio of 25.40. | AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2023. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABBV is 13.19 vs. an industry ratio of 25.40. | AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2023. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABBV is 13.19 vs. an industry ratio of 25.40. | In the past year ABBV has beat the expectations every quarter. AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2023. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABBV is 13.19 vs. an industry ratio of 25.40. |
22,104 | 2023-10-26 00:00:00 UTC | Lilly's bowel disease drug gets US FDA nod for treatment in adults | ABBV | https://www.nasdaq.com/articles/lillys-bowel-disease-drug-gets-us-fda-nod-for-treatment-in-adults | null | null | Adds details about the approval and launch in paragraphs 2-7
Oct 26 (Reuters) - Eli Lilly and Co LLY.N said on Thursday that the U.S. health regulator had approved its drug for treating adults with moderate-to-severe active ulcerative colitis, a type of chronic inflammatory bowel disease.
The drug, which will be availa... | The drug, which will be available in the United States in coming weeks and sold under brand name Omvoh, is among Lilly's potential growth drivers for this decade alongside tirzepatide for obesity, lebrikizumab for atopic dermatitis or eczema and pirtobrutinib for cancer. The approval was based on data from late-stage s... | Adds details about the approval and launch in paragraphs 2-7 Oct 26 (Reuters) - Eli Lilly and Co LLY.N said on Thursday that the U.S. health regulator had approved its drug for treating adults with moderate-to-severe active ulcerative colitis, a type of chronic inflammatory bowel disease. Ulcerative colitis is a condit... | Adds details about the approval and launch in paragraphs 2-7 Oct 26 (Reuters) - Eli Lilly and Co LLY.N said on Thursday that the U.S. health regulator had approved its drug for treating adults with moderate-to-severe active ulcerative colitis, a type of chronic inflammatory bowel disease. The drug, which will be availa... | Adds details about the approval and launch in paragraphs 2-7 Oct 26 (Reuters) - Eli Lilly and Co LLY.N said on Thursday that the U.S. health regulator had approved its drug for treating adults with moderate-to-severe active ulcerative colitis, a type of chronic inflammatory bowel disease. The drug, which will be availa... |
22,105 | 2023-10-26 00:00:00 UTC | Invest in Dividend Aristocrat Stocks with the NOBL ETF | ABBV | https://www.nasdaq.com/articles/invest-in-dividend-aristocrat-stocks-with-the-nobl-etf | null | null | A Dividend Aristocrat is a company in the S&P 500 (SPX) that not only pays a dividend but has also increased the size of its dividend payout for at least 25 years in a row. These are the types of prudent companies that care about shareholder returns that you want to invest in for the long term, and thanks to the ProSha... | An impressive five of NOBL's top 10 holdings feature 'Perfect 10' Smart Scores -- ExxonMobil, AbbVie (NYSE:ABBV), Procter & Gamble, Cintas (NASDAQ:CTAS), and IBM (NYSE:IBM). Top holding General Dynamics (NYSE:GD) has a proud history of increasing its dividend payout for 29 straight years. At the same time, NOBL’s secon... | An impressive five of NOBL's top 10 holdings feature 'Perfect 10' Smart Scores -- ExxonMobil, AbbVie (NYSE:ABBV), Procter & Gamble, Cintas (NASDAQ:CTAS), and IBM (NYSE:IBM). Further down the list of top 10 holdings, well-known blue-chip names like Walmart (NYSE:WMT) and Procter & Gamble (NYSE:PG) have increased their d... | An impressive five of NOBL's top 10 holdings feature 'Perfect 10' Smart Scores -- ExxonMobil, AbbVie (NYSE:ABBV), Procter & Gamble, Cintas (NASDAQ:CTAS), and IBM (NYSE:IBM). NOBL describes itself as the “only ETF focusing exclusively on the S&P 500 Dividend Aristocrats—high-quality companies that have not just paid div... | An impressive five of NOBL's top 10 holdings feature 'Perfect 10' Smart Scores -- ExxonMobil, AbbVie (NYSE:ABBV), Procter & Gamble, Cintas (NASDAQ:CTAS), and IBM (NYSE:IBM). A Dividend Aristocrat is a company in the S&P 500 (SPX) that not only pays a dividend but has also increased the size of its dividend payout for a... |
22,106 | 2023-10-26 00:00:00 UTC | Why Earnings Season Could Be Great for AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-abbvie-abbv-0 | null | null | Investors are always looking for stocks that are poised to beat at earnings season and AbbVie Inc. ABBV, may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because AbbVie is seeing favorable earnings estimate revision activity as of lat... | After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ABBV in this report. Clearly, recent earnings estimate revisions suggest that good things are ahead for AbbVie, and that a beat mig... | Clearly, recent earnings estimate revisions suggest that good things are ahead for AbbVie, and that a beat might be in the cards for the upcoming report. Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors are always looking for stocks th... | This suggests that analysts have very recently bumped up their estimates for ABBV, giving the stock a Zacks Earnings ESP of +0.08% heading into earnings season. Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always look... | This suggests that analysts have very recently bumped up their estimates for ABBV, giving the stock a Zacks Earnings ESP of +0.08% heading into earnings season. Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always look... |
22,107 | 2023-10-26 00:00:00 UTC | Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond | ABBV | https://www.nasdaq.com/articles/got-%241000-these-2-stocks-could-be-bargain-buys-for-2023-and-beyond-1 | null | null | While equity markets this year have recovered some of ground lost from the plunge of 2022, plenty of companies are still struggling. Some of them, though, clearly have the tools to rebound eventually and deliver solid returns to patient investors. Two stocks in that category are AbbVie (NYSE: ABBV) and Tandem Diabetes ... | Two stocks in that category are AbbVie (NYSE: ABBV) and Tandem Diabetes Care (NASDAQ: TNDM). AbbVie There is plenty to like about AbbVie's business: It boasts a rich lineup of drugs treating conditions across multiple therapeutic areas, and a deep pipeline that should yield more innovative medicines. Then, of course, t... | Two stocks in that category are AbbVie (NYSE: ABBV) and Tandem Diabetes Care (NASDAQ: TNDM). AbbVie There is plenty to like about AbbVie's business: It boasts a rich lineup of drugs treating conditions across multiple therapeutic areas, and a deep pipeline that should yield more innovative medicines. Then, of course, t... | Two stocks in that category are AbbVie (NYSE: ABBV) and Tandem Diabetes Care (NASDAQ: TNDM). That's why AbbVie is down 9.9% this year, and at these levels, the company looks like a good pick, especially for investors on the market for blue chip dividend stocks. AbbVie There is plenty to like about AbbVie's business: It... | Two stocks in that category are AbbVie (NYSE: ABBV) and Tandem Diabetes Care (NASDAQ: TNDM). AbbVie There is plenty to like about AbbVie's business: It boasts a rich lineup of drugs treating conditions across multiple therapeutic areas, and a deep pipeline that should yield more innovative medicines. Then, of course, t... |
22,108 | 2023-10-26 00:00:00 UTC | Notable Thursday Option Activity: ABBV, ANET, WDC | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-abbv-anet-wdc | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 26,502 contracts have traded so far, representing approximately 2.7 million underlying shares. That amounts to about 61.9% of ABBV's average daily trading volume over the p... | Especially high volume was seen for the $150 strike call option expiring January 19, 2024, with 7,616 contracts trading so far today, representing approximately 761,600 underlying shares of ABBV. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ... | Especially high volume was seen for the $150 strike call option expiring January 19, 2024, with 7,616 contracts trading so far today, representing approximately 761,600 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $150 strike highlighted in orange: Arista Ne... | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 26,502 contracts have traded so far, representing approximately 2.7 million underlying shares. Especially high volume was seen for the $150 strike call option expiring Janu... | Below is a chart showing WDC's trailing twelve month trading history, with the $45 strike highlighted in orange: For the various different available expirations for ABBV options, ANET options, or WDC options, visit StockOptionsChannel.com. Among the underlying components of the S&P 500 index, we saw noteworthy options ... |
22,109 | 2023-10-25 00:00:00 UTC | ABBV Factor-Based Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-factor-based-stock-analysis-7 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,110 | 2023-10-25 00:00:00 UTC | USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day | ABBV | https://www.nasdaq.com/articles/usa-compression-and-disney-have-been-highlighted-as-zacks-bull-and-bear-of-the-day | null | null | For Immediate Release
Chicago, IL – October 25, 2023 – Zacks Equity Research shares USA Compression Partners USAC as the Bull of the Day and Disney DIS as the Bear of the Day. In addition, Zacks Equity Research provides analysis on AbbVie ABBV, Amgen AMGN and Gilead Sciences GILD.
Here is a synopsis of all five stocks.... | In addition, Zacks Equity Research provides analysis on AbbVie ABBV, Amgen AMGN and Gilead Sciences GILD. High-quality dividend stocks like AbbVie, Amgen and Gilead Sciences with an impressive dividend history, might fetch promising returns for investors.These companies have consistently announced dividend hikes, which... | In addition, Zacks Equity Research provides analysis on AbbVie ABBV, Amgen AMGN and Gilead Sciences GILD. Click to get this free report Amgen Inc. (AMGN) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report The Walt Disney Company (DIS) : Free Stock Analysis Report AbbVie Inc. (ABBV) :... | Click to get this free report Amgen Inc. (AMGN) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report The Walt Disney Company (DIS) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report USA Compression Partners, LP (USAC) : Free Stock Analysis Report To read this ... | In addition, Zacks Equity Research provides analysis on AbbVie ABBV, Amgen AMGN and Gilead Sciences GILD. High-quality dividend stocks like AbbVie, Amgen and Gilead Sciences with an impressive dividend history, might fetch promising returns for investors.These companies have consistently announced dividend hikes, which... |
22,111 | 2023-10-24 00:00:00 UTC | VTV: A Must-Watch ETF for Value Investors | ABBV | https://www.nasdaq.com/articles/vtv%3A-a-must-watch-etf-for-value-investors | null | null | Value investing may not sound as exciting as investing in the next hot growth stock, but it’s a time-honored investing style that some of the most renowned investors of all time have used to generate tremendous returns over the years. In an uncertain market environment like the current one, investing in a well-establis... | Meanwhile, household names like Johnson & Johnson (NYSE:JNJ), AbbVie (NYSE:ABBV), and Merck (NYSE:MRK) carry the flag for the healthcare sector. Just looking at a few of VTV’s top holdings for comparison, ExxonMobil currently trades for 11.7 times earnings, JPMorgan Chase has a valuation of just 8.7 times earnings, and... | Just looking at a few of VTV’s top holdings for comparison, ExxonMobil currently trades for 11.7 times earnings, JPMorgan Chase has a valuation of just 8.7 times earnings, and AbbVie has a valuation of 13.2 times earnings. Meanwhile, household names like Johnson & Johnson (NYSE:JNJ), AbbVie (NYSE:ABBV), and Merck (NYSE... | Just looking at a few of VTV’s top holdings for comparison, ExxonMobil currently trades for 11.7 times earnings, JPMorgan Chase has a valuation of just 8.7 times earnings, and AbbVie has a valuation of 13.2 times earnings. Meanwhile, household names like Johnson & Johnson (NYSE:JNJ), AbbVie (NYSE:ABBV), and Merck (NYSE... | Just looking at a few of VTV’s top holdings for comparison, ExxonMobil currently trades for 11.7 times earnings, JPMorgan Chase has a valuation of just 8.7 times earnings, and AbbVie has a valuation of 13.2 times earnings. Meanwhile, household names like Johnson & Johnson (NYSE:JNJ), AbbVie (NYSE:ABBV), and Merck (NYSE... |
22,112 | 2023-10-24 00:00:00 UTC | Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline | ABBV | https://www.nasdaq.com/articles/earnings-preview%3A-pfizer-pfe-q3-earnings-expected-to-decline | null | null | Pfizer (PFE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor th... | Expected Results of an Industry Player Another stock from the Zacks Large Cap Pharmaceuticals industry, AbbVie (ABBV), is soon expected to post earnings of $2.87 per share for the quarter ended September 2023. The consensus EPS estimate for AbbVie has been revised 0.5% higher over the last 30 days to the current level.... | This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that AbbVie will beat the consensus EPS estimate. Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click her... | This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that AbbVie will beat the consensus EPS estimate. Expected Results of an Industry Player Another stock from the Zacks Large Cap Pharmaceuticals industry, AbbVie (ABBV), is soon expected to post earnings of $2.87 per sh... | This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that AbbVie will beat the consensus EPS estimate. Expected Results of an Industry Player Another stock from the Zacks Large Cap Pharmaceuticals industry, AbbVie (ABBV), is soon expected to post earnings of $2.87 per sh... |
22,113 | 2023-10-24 00:00:00 UTC | 3 Biotech Stocks With Decent Dividend for a Steady Return | ABBV | https://www.nasdaq.com/articles/3-biotech-stocks-with-decent-dividend-for-a-steady-return | null | null | The Zacks Biomedical and Genetics industry continues to grapple with issues like unfavorable foreign currency fluctuations that affect premium growth. Also, volatile global equity markets and low bond yields put enormous pressure on the insurer’s capital position. Amid volatile market conditions, companies with an impr... | High-quality dividend stocks like AbbVie ABBV, Amgen AMGN and Gilead Sciences GILD with an impressive dividend history, might fetch promising returns for investors.These companies have consistently announced dividend hikes, which highlight their pro-shareholder stance. AbbVie: Headquartered in North Chicago, IL, AbbVie... | Click to get this free report Amgen Inc. (AMGN) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. High-quality dividend stocks like AbbVie ABBV, Amgen AMGN and Gilead Sciences GILD with an ... | High-quality dividend stocks like AbbVie ABBV, Amgen AMGN and Gilead Sciences GILD with an impressive dividend history, might fetch promising returns for investors.These companies have consistently announced dividend hikes, which highlight their pro-shareholder stance. Click to get this free report Amgen Inc. (AMGN) : ... | High-quality dividend stocks like AbbVie ABBV, Amgen AMGN and Gilead Sciences GILD with an impressive dividend history, might fetch promising returns for investors.These companies have consistently announced dividend hikes, which highlight their pro-shareholder stance. AbbVie: Headquartered in North Chicago, IL, AbbVie... |
22,114 | 2023-10-24 00:00:00 UTC | Allergan Announces Positive Results From Phase 3 Studies Of TrenibotulinumtoxinE In Glabella Lines | ABBV | https://www.nasdaq.com/articles/allergan-announces-positive-results-from-phase-3-studies-of-trenibotulinumtoxine-in | null | null | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced positive results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines (M21-500 and M21-508).
The Phase 3 studies evaluated the safety and efficacy of BoNT/E versus p... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced positive results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines (M21-500 and M21-508). The Phase 3 studies evaluated the safety and efficacy of BoNT/E versus p... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced positive results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines (M21-500 and M21-508). The Phase 3 studies evaluated the safety and efficacy of BoNT/E versus p... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced positive results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines (M21-500 and M21-508). The Phase 3 studies evaluated the safety and efficacy of BoNT/E versus p... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced positive results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines (M21-500 and M21-508). The Phase 3 studies evaluated the safety and efficacy of BoNT/E versus p... |
22,115 | 2023-10-23 00:00:00 UTC | AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-sees-a-more-significant-dip-than-broader-market%3A-some-facts-to-know | null | null | In the latest trading session, AbbVie (ABBV) closed at $144.73, marking a -1.03% move from the previous day. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop of 0.58%, and the technology-dominated Nasdaq saw an increase of 0.27%.
The the stock of drugmaker has fallen by 4.26% in... | In the latest trading session, AbbVie (ABBV) closed at $144.73, marking a -1.03% move from the previous day. The investment community will be closely monitoring the performance of AbbVie in its forthcoming earnings report. It is also important to note the recent changes to analyst estimates for AbbVie. | In the latest trading session, AbbVie (ABBV) closed at $144.73, marking a -1.03% move from the previous day. The investment community will be closely monitoring the performance of AbbVie in its forthcoming earnings report. It is also important to note the recent changes to analyst estimates for AbbVie. | In the latest trading session, AbbVie (ABBV) closed at $144.73, marking a -1.03% move from the previous day. The investment community will be closely monitoring the performance of AbbVie in its forthcoming earnings report. It is also important to note the recent changes to analyst estimates for AbbVie. | In the latest trading session, AbbVie (ABBV) closed at $144.73, marking a -1.03% move from the previous day. The investment community will be closely monitoring the performance of AbbVie in its forthcoming earnings report. It is also important to note the recent changes to analyst estimates for AbbVie. |
22,116 | 2023-10-23 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-17 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,117 | 2023-10-23 00:00:00 UTC | Stocks Set to Open Lower as Investors Await Key U.S. Inflation Data and Big Tech Earnings | ABBV | https://www.nasdaq.com/articles/stocks-set-to-open-lower-as-investors-await-key-u.s.-inflation-data-and-big-tech-earnings | null | null | December S&P 500 futures (ESZ23) are down -0.76%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.92% this morning as the benchmark U.S. 10-year yield hit 5% for the first time since 2007 while market participants geared up for earnings reports from some of the biggest tech heavyweights as well as the releas... | Third-quarter earnings season kicks into full gear, and investors await fresh reports from major global companies this week, including Microsoft (MSFT), Alphabet (GOOGL), Visa (V), Coca-Cola (KO), Meta Platforms (META), Boeing (BA), Amazon.com (AMZN), Mastercard (MA), Merck (MRK), Intel (INTC), Altria (MO), Exxon Mobil... | Third-quarter earnings season kicks into full gear, and investors await fresh reports from major global companies this week, including Microsoft (MSFT), Alphabet (GOOGL), Visa (V), Coca-Cola (KO), Meta Platforms (META), Boeing (BA), Amazon.com (AMZN), Mastercard (MA), Merck (MRK), Intel (INTC), Altria (MO), Exxon Mobil... | Third-quarter earnings season kicks into full gear, and investors await fresh reports from major global companies this week, including Microsoft (MSFT), Alphabet (GOOGL), Visa (V), Coca-Cola (KO), Meta Platforms (META), Boeing (BA), Amazon.com (AMZN), Mastercard (MA), Merck (MRK), Intel (INTC), Altria (MO), Exxon Mobil... | Third-quarter earnings season kicks into full gear, and investors await fresh reports from major global companies this week, including Microsoft (MSFT), Alphabet (GOOGL), Visa (V), Coca-Cola (KO), Meta Platforms (META), Boeing (BA), Amazon.com (AMZN), Mastercard (MA), Merck (MRK), Intel (INTC), Altria (MO), Exxon Mobil... |
22,118 | 2023-10-23 00:00:00 UTC | AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-to-report-q3-earnings%3A-whats-in-the-cards-0 | null | null | AbbVie ABBV will report third-quarter 2023 results on Oct 27, before market open. In the last reported quarter, the company delivered an earnings surprise of 4.30%.
Factors to Consider
AbbVie’s top line is expected to have been driven by sales of new immunology drugs, Skyrizi and Rinvoq, which registered strong growth ... | Factors to Consider AbbVie’s top line is expected to have been driven by sales of new immunology drugs, Skyrizi and Rinvoq, which registered strong growth in the past few quarters. During the third quarter, AbbVie reported data from separate head-to-head studies, which showed that treatment with Skyrizi exhibited super... | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV will report third-quarter 2023 re... | Earnings ESP: AbbVie has an Earnings ESP of -0.31% as the Most Accurate Estimate of $2.86 per share is lower than the Zacks Consensus Estimate of $2.87. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock An... | AbbVie ABBV will report third-quarter 2023 results on Oct 27, before market open. Factors to Consider AbbVie’s top line is expected to have been driven by sales of new immunology drugs, Skyrizi and Rinvoq, which registered strong growth in the past few quarters. During the third quarter, AbbVie reported data from separ... |
22,119 | 2023-10-20 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-16 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,120 | 2023-10-20 00:00:00 UTC | Earnings Preview: AbbVie (ABBV) Q3 Earnings Expected to Decline | ABBV | https://www.nasdaq.com/articles/earnings-preview%3A-abbvie-abbv-q3-earnings-expected-to-decline | null | null | AbbVie (ABBV) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor t... | AbbVie (ABBV) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2023. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently b... | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended Septe... | For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. AbbVie (ABBV) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended Septembe... | AbbVie (ABBV) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2023. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently b... |
22,121 | 2023-10-20 00:00:00 UTC | 7 Dividend Stocks to Buy and Hold Forever and Ever | ABBV | https://www.nasdaq.com/articles/7-dividend-stocks-to-buy-and-hold-forever-and-ever | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Recently, investors searching for dividend stocks to buy have seen more opportunity.
Some looking for income over a longer term horizon have flooded into the bond market. Yields there are rising, and some, like treasury bonds, are nearly risk free. That has... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) has overcome a significant hurdle that often stifles pharmaceutical firms and gone from a dicey proposition to one of the better dividend stocks to buy in the space. Humira’s decline will not be the death of AbbVie by any means. In the midst... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) has overcome a significant hurdle that often stifles pharmaceutical firms and gone from a dicey proposition to one of the better dividend stocks to buy in the space. Humira’s decline will not be the death of AbbVie by any means. In the midst... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) has overcome a significant hurdle that often stifles pharmaceutical firms and gone from a dicey proposition to one of the better dividend stocks to buy in the space. Humira’s decline will not be the death of AbbVie by any means. In the midst... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) has overcome a significant hurdle that often stifles pharmaceutical firms and gone from a dicey proposition to one of the better dividend stocks to buy in the space. Humira’s decline will not be the death of AbbVie by any means. In the midst... |
22,122 | 2023-10-20 00:00:00 UTC | The Zacks Analyst Blog Highlights Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-visa-abbvie-bhp-group-caterpillar-and-boston-scientific | null | null | For Immediate Release
Chicago, IL – October 20, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa Inc. V, AbbVie Inc. A... | Stocks recently featured in the blog include: Visa Inc. V, AbbVie Inc. ABBV, BHP Group Ltd. BHP, Caterpillar Inc. CAT and Boston Scientific Corp. BSX. Here are highlights from Thursday’s Analyst Blog: Top Research Reports for Visa, AbbVie and BHP The Zacks Research Daily presents the best research output of our analyst... | Stocks recently featured in the blog include: Visa Inc. V, AbbVie Inc. ABBV, BHP Group Ltd. BHP, Caterpillar Inc. CAT and Boston Scientific Corp. BSX. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., AbbVie Inc. and BHP Group Ltd. Click to get this free report Visa Inc. (V) ... | Here are highlights from Thursday’s Analyst Blog: Top Research Reports for Visa, AbbVie and BHP The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., AbbVie Inc. and BHP Group Ltd. Click to get this f... | Stocks recently featured in the blog include: Visa Inc. V, AbbVie Inc. ABBV, BHP Group Ltd. BHP, Caterpillar Inc. CAT and Boston Scientific Corp. BSX. Here are highlights from Thursday’s Analyst Blog: Top Research Reports for Visa, AbbVie and BHP The Zacks Research Daily presents the best research output of our analyst... |
22,123 | 2023-10-19 00:00:00 UTC | Noteworthy ETF Inflows: IWY, TSLA, LLY, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-iwy-tsla-lly-abbv | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Top 200 Growth ETF (Symbol: IWY) where we have detected an approximate $431.9 million dollar inflow -- that's a 6.5% increase week over week in outstanding units (from 42,400... | Among the largest underlying components of IWY, in trading today Tesla Inc (Symbol: TSLA) is down about 8.1%, Eli Lilly (Symbol: LLY) is off about 4%, and AbbVie Inc (Symbol: ABBV) is lower by about 3.1%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate ... | Among the largest underlying components of IWY, in trading today Tesla Inc (Symbol: TSLA) is down about 8.1%, Eli Lilly (Symbol: LLY) is off about 4%, and AbbVie Inc (Symbol: ABBV) is lower by about 3.1%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price performance... | Among the largest underlying components of IWY, in trading today Tesla Inc (Symbol: TSLA) is down about 8.1%, Eli Lilly (Symbol: LLY) is off about 4%, and AbbVie Inc (Symbol: ABBV) is lower by about 3.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one s... | Among the largest underlying components of IWY, in trading today Tesla Inc (Symbol: TSLA) is down about 8.1%, Eli Lilly (Symbol: LLY) is off about 4%, and AbbVie Inc (Symbol: ABBV) is lower by about 3.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one s... |
22,124 | 2023-10-19 00:00:00 UTC | 7 Dividend Aristocrats to Batten Down the Hatches | ABBV | https://www.nasdaq.com/articles/7-dividend-aristocrats-to-batten-down-the-hatches | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
With market uncertainty practically being the only form of certainty available, investors should consider dividend aristocrats. By definition, companies under this category belong in the S&P 500 index which consistently raises their dividends for at least t... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com A pharmaceutical giant, AbbVie (NYSE:ABBV) might fit into the three-hole scheme regarding dividend aristocrats for your portfolio. However, with its buyout of Allergan, AbbVie stands to benefit handsomely from certain social dynamics. So, I anticipate a massiv... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com A pharmaceutical giant, AbbVie (NYSE:ABBV) might fit into the three-hole scheme regarding dividend aristocrats for your portfolio. However, with its buyout of Allergan, AbbVie stands to benefit handsomely from certain social dynamics. So, I anticipate a massiv... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com A pharmaceutical giant, AbbVie (NYSE:ABBV) might fit into the three-hole scheme regarding dividend aristocrats for your portfolio. However, with its buyout of Allergan, AbbVie stands to benefit handsomely from certain social dynamics. So, I anticipate a massiv... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com A pharmaceutical giant, AbbVie (NYSE:ABBV) might fit into the three-hole scheme regarding dividend aristocrats for your portfolio. However, with its buyout of Allergan, AbbVie stands to benefit handsomely from certain social dynamics. So, I anticipate a massiv... |
22,125 | 2023-10-19 00:00:00 UTC | Is AbbVie Stock Too Pricey to Touch Right Now? | ABBV | https://www.nasdaq.com/articles/is-abbvie-stock-too-pricey-to-touch-right-now | null | null | For a company in the midst of a transition away from the medicine that made it a star performer over the last decade, AbbVie's (NYSE: ABBV) valuation looks surprisingly high. Why is the market pricing a business, which is barely expecting much growth over the next couple of years, so expensively? The market's expectati... | With so many programs in the pipeline approaching maturity -- whether they're expansions of a commercialized drug's indications or something new altogether -- there's little chance of AbbVie's fortunes falling into hard times. For a company in the midst of a transition away from the medicine that made it a star perform... | For a company in the midst of a transition away from the medicine that made it a star performer over the last decade, AbbVie's (NYSE: ABBV) valuation looks surprisingly high. At the moment, AbbVie's price-to-earnings (P/E) ratio is 31. There are a few possibilities as to why a stock's valuation could be higher than its... | 10 stocks we like better than AbbVie When our analyst team has a stock tip, it can pay to listen. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! For a company in the midst of a transition away from the medicine that made it a star performe... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! For a company in the midst of a transition away from the medicine that made it a star performer over the last decade, AbbVie's (NYSE: ABBV) valuation looks surprisingly high. At the moment, Ab... |
22,126 | 2023-10-19 00:00:00 UTC | Is Johnson & Johnson Still a Good Dividend Stock to Buy? | ABBV | https://www.nasdaq.com/articles/is-johnson-johnson-still-a-good-dividend-stock-to-buy-0 | null | null | It's been a transformational year for Johnson & Johnson (NYSE: JNJ). This August, the company spun off its consumer health division into a new company called Kenvue (NYSE: KVUE).
Now that Kenvue sells Listerine, Q-tips, and Tylenol, investors are concerned that the steady dividend raises Johnson & Johnson, or J&J, is f... | Stelara, Xarelto, a blood thinner, and Imbruvica, a blood cancer drug that J&J sells in partnership with AbbVie, are on a list of top-selling treatments eligible next year for new drug-price negotiations with Medicare. In addition to beating Wall Street's estimates, J&J raised its own guidance regarding sales and earni... | Stelara, Xarelto, a blood thinner, and Imbruvica, a blood cancer drug that J&J sells in partnership with AbbVie, are on a list of top-selling treatments eligible next year for new drug-price negotiations with Medicare. The company expects to report total sales that rise 7.7% at the midpoint of its guided range. Adjuste... | Stelara, Xarelto, a blood thinner, and Imbruvica, a blood cancer drug that J&J sells in partnership with AbbVie, are on a list of top-selling treatments eligible next year for new drug-price negotiations with Medicare. Johnson & Johnson raised its dividend payout for the 61st consecutive year this April, and further ra... | Stelara, Xarelto, a blood thinner, and Imbruvica, a blood cancer drug that J&J sells in partnership with AbbVie, are on a list of top-selling treatments eligible next year for new drug-price negotiations with Medicare. Stelara, a biologic drug for the treatment of psoriasis and bowel inflammation, is a key growth drive... |
22,127 | 2023-10-19 00:00:00 UTC | Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now | null | null | A smart beta exchange traded fund, the Invesco Pharmaceuticals ETF (PJP) debuted on 06/23/2005, and offers broad exposure to the Health Care ETFs category of the market.
What Are Smart Beta ETFs?
The ETF industry has long been dominated by products based on market cap weighted indexes, a strategy created to reflect the... | Taking into account individual holdings, Amgen Inc (AMGN) accounts for about 6.45% of the fund's total assets, followed by Eli Lilly & Co (LLY) and Abbvie Inc (ABBV). Click to get this free report Invesco Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc.... | Click to get this free report Invesco Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharmaceutical... | Click to get this free report Invesco Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharmaceutical... | Taking into account individual holdings, Amgen Inc (AMGN) accounts for about 6.45% of the fund's total assets, followed by Eli Lilly & Co (LLY) and Abbvie Inc (ABBV). Click to get this free report Invesco Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc.... |
22,128 | 2023-10-18 00:00:00 UTC | ABBV Factor-Based Stock Analysis | ABBV | https://www.nasdaq.com/articles/abbv-factor-based-stock-analysis-6 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,129 | 2023-10-18 00:00:00 UTC | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-attracting-investor-attention%3A-here-is-what-you-should-know-10 | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this drugmaker have returned -2.8%, compared to the Zacks S&P 500 composite's -1.... | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has gained 0.5%. AbbVie is expected to post earnings of $2.87 per share for the current quarter, representing a year-over-year change of -21.6%. | Last Reported Results and Surprise History AbbVie reported revenues of $13.87 billion in the last reported quarter, representing a year-over-year change of -4.9%. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbV... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which Abb... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which Abb... |
22,130 | 2023-10-17 00:00:00 UTC | Takeda Settles Tax Dispute With Irish Revenue Commissioners Over Break Fee Received By Shire | ABBV | https://www.nasdaq.com/articles/takeda-settles-tax-dispute-with-irish-revenue-commissioners-over-break-fee-received-by | null | null | (RTTNews) - Takeda (TAK) said it agreed with the Irish Revenue Commissioners to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc in October 2014 from AbbVie Inc., for 130 million euros, resulting in a tax expense reduction of about JPY 63 billion for Takeda.
On November... | (RTTNews) - Takeda (TAK) said it agreed with the Irish Revenue Commissioners to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc in October 2014 from AbbVie Inc., for 130 million euros, resulting in a tax expense reduction of about JPY 63 billion for Takeda. While Taked... | (RTTNews) - Takeda (TAK) said it agreed with the Irish Revenue Commissioners to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc in October 2014 from AbbVie Inc., for 130 million euros, resulting in a tax expense reduction of about JPY 63 billion for Takeda. On November... | (RTTNews) - Takeda (TAK) said it agreed with the Irish Revenue Commissioners to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc in October 2014 from AbbVie Inc., for 130 million euros, resulting in a tax expense reduction of about JPY 63 billion for Takeda. On November... | (RTTNews) - Takeda (TAK) said it agreed with the Irish Revenue Commissioners to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc in October 2014 from AbbVie Inc., for 130 million euros, resulting in a tax expense reduction of about JPY 63 billion for Takeda. While Taked... |
22,131 | 2023-10-17 00:00:00 UTC | 3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off | ABBV | https://www.nasdaq.com/articles/3-supercharged-dividend-stocks-to-buy-if-theres-a-stock-market-sell-off-9 | null | null | Industries with endless demand are great places to find dividend stocks. Healthcare might be the best example of this. No matter how much technology changes, the need to prevent and treat disease will never disappear. Sure, new treatments and solutions can change the game anytime, but the best players are the companies... | Investors should monitor the stock and look for a dividend yield they can live with (it's currently 4%) until AbbVie shows signs of returning growth. AbbVie Pharmaceutical company AbbVie (NYSE: ABBV) was formed when its sister company, Abbott Laboratories, spun it off in 2013. AbbVie's dividend roots go back decades be... | AbbVie Pharmaceutical company AbbVie (NYSE: ABBV) was formed when its sister company, Abbott Laboratories, spun it off in 2013. AbbVie's dividend roots go back decades before the split, and the company has raised its dividend every year since becoming its own corporation. Investors enjoyed robust years of dividend grow... | AbbVie's dividend roots go back decades before the split, and the company has raised its dividend every year since becoming its own corporation. ABBV PE Ratio (Forward) data by YCharts It's hard to justify a very high valuation without earnings growth, so the stock's price tag at 13 times earnings could come under pres... | AbbVie's dividend roots go back decades before the split, and the company has raised its dividend every year since becoming its own corporation. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie Pharmaceutical company AbbVie (NYSE: ABB... |
22,132 | 2023-10-17 00:00:00 UTC | AbbVie's DLBCL Drug EPKINLY, Crohn's Disease Drug RINVOQ Get Health Canada Approval | ABBV | https://www.nasdaq.com/articles/abbvies-dlbcl-drug-epkinly-crohns-disease-drug-rinvoq-get-health-canada-approval | null | null | (RTTNews) - AbbVie (ABBV) announced Tuesday that Health Canada has approved EPKINLY (epcoritamab injection/epcoritamab for injection) to treat Relapsed or Refractory Diffuse Large B-Cell Lymphoma or DLBCL, as well as RINVOQ (upadacitinib) to treat moderately to severely active Crohn's Disease.
EPKINLY has received the ... | (RTTNews) - AbbVie (ABBV) announced Tuesday that Health Canada has approved EPKINLY (epcoritamab injection/epcoritamab for injection) to treat Relapsed or Refractory Diffuse Large B-Cell Lymphoma or DLBCL, as well as RINVOQ (upadacitinib) to treat moderately to severely active Crohn's Disease. The drug is being co-deve... | (RTTNews) - AbbVie (ABBV) announced Tuesday that Health Canada has approved EPKINLY (epcoritamab injection/epcoritamab for injection) to treat Relapsed or Refractory Diffuse Large B-Cell Lymphoma or DLBCL, as well as RINVOQ (upadacitinib) to treat moderately to severely active Crohn's Disease. The drug is being co-deve... | (RTTNews) - AbbVie (ABBV) announced Tuesday that Health Canada has approved EPKINLY (epcoritamab injection/epcoritamab for injection) to treat Relapsed or Refractory Diffuse Large B-Cell Lymphoma or DLBCL, as well as RINVOQ (upadacitinib) to treat moderately to severely active Crohn's Disease. The drug is being co-deve... | (RTTNews) - AbbVie (ABBV) announced Tuesday that Health Canada has approved EPKINLY (epcoritamab injection/epcoritamab for injection) to treat Relapsed or Refractory Diffuse Large B-Cell Lymphoma or DLBCL, as well as RINVOQ (upadacitinib) to treat moderately to severely active Crohn's Disease. The drug is being co-deve... |
22,133 | 2023-10-17 00:00:00 UTC | Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-proshares-sp-500-dividend-aristocrats-etf-nobl-a-strong-etf-right-now-8 | null | null | Launched on 10/09/2013, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) is a smart beta exchange traded fund offering broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Products that are based on market cap weighted indexes, which are strategies designed to reflect... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... |
22,134 | 2023-10-16 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-heres-why | null | null | In the latest market close, AbbVie (ABBV) reached $147.23, with a -0.49% movement compared to the previous day. The stock's change was less than the S&P 500's daily gain of 1.06%. Meanwhile, the Dow experienced a rise of 0.93%, and the technology-dominated Nasdaq saw an increase of 1.2%.
The drugmaker's stock has dropp... | In the latest market close, AbbVie (ABBV) reached $147.23, with a -0.49% movement compared to the previous day. Market participants will be closely following the financial results of AbbVie in its upcoming release. On that day, AbbVie is projected to report earnings of $2.87 per share, which would represent a year-over... | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. In the latest market close, AbbVie (ABBV) reached $147.23, with a -0.49% movement compared to the previous day. Market participants will be closely following the financial results of AbbVie in its... | In the latest market close, AbbVie (ABBV) reached $147.23, with a -0.49% movement compared to the previous day. Market participants will be closely following the financial results of AbbVie in its upcoming release. On that day, AbbVie is projected to report earnings of $2.87 per share, which would represent a year-over... | In the latest market close, AbbVie (ABBV) reached $147.23, with a -0.49% movement compared to the previous day. Market participants will be closely following the financial results of AbbVie in its upcoming release. On that day, AbbVie is projected to report earnings of $2.87 per share, which would represent a year-over... |
22,135 | 2023-10-16 00:00:00 UTC | Notable Monday Option Activity: MRTN, ABBV, GILD | ABBV | https://www.nasdaq.com/articles/notable-monday-option-activity%3A-mrtn-abbv-gild | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Marten Transport Ltd (Symbol: MRTN), where a total of 1,085 contracts have traded so far, representing approximately 108,500 underlying shares. That amounts to about 46.2% of MRTN's average daily trading volume ... | Particularly high volume was seen for the $160 strike call option expiring December 15, 2023, with 10,146 contracts trading so far today, representing approximately 1.0 million underlying shares of ABBV. Below is a chart showing MRTN's trailing twelve month trading history, with the $17.50 strike highlighted in orange:... | Below is a chart showing MRTN's trailing twelve month trading history, with the $17.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 17,261 contracts thus far today. That number of contracts represents approximately 1.7 million underlying shares, working out to a sizeable 45.6%... | Particularly high volume was seen for the $160 strike call option expiring December 15, 2023, with 10,146 contracts trading so far today, representing approximately 1.0 million underlying shares of ABBV. Below is a chart showing MRTN's trailing twelve month trading history, with the $17.50 strike highlighted in orange:... | Below is a chart showing GILD's trailing twelve month trading history, with the $77 strike highlighted in orange: For the various different available expirations for MRTN options, ABBV options, or GILD options, visit StockOptionsChannel.com. Below is a chart showing MRTN's trailing twelve month trading history, with th... |
22,136 | 2023-10-15 00:00:00 UTC | AbbVie : Phase 3 Study Of Skyrizi In Crohn's Disease Meets All Primary And Secondary Endpoints | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-phase-3-study-of-skyrizi-in-crohns-disease-meets-all-primary-and-secondary | null | null | (RTTNews) - AbbVie (ABBV) presented positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (Skyrizi, 600 mg intravenous [IV] at week 0, 4 and 8 and 360 mg subcutaneous [SC] starting at week 12 and every 8 weeks thereafter) compared to ustekinumab (STELARA, I... | (RTTNews) - AbbVie (ABBV) presented positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (Skyrizi, 600 mg intravenous [IV] at week 0, 4 and 8 and 360 mg subcutaneous [SC] starting at week 12 and every 8 weeks thereafter) compared to ustekinumab (STELARA, I... | (RTTNews) - AbbVie (ABBV) presented positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (Skyrizi, 600 mg intravenous [IV] at week 0, 4 and 8 and 360 mg subcutaneous [SC] starting at week 12 and every 8 weeks thereafter) compared to ustekinumab (STELARA, I... | (RTTNews) - AbbVie (ABBV) presented positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (Skyrizi, 600 mg intravenous [IV] at week 0, 4 and 8 and 360 mg subcutaneous [SC] starting at week 12 and every 8 weeks thereafter) compared to ustekinumab (STELARA, I... | (RTTNews) - AbbVie (ABBV) presented positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (Skyrizi, 600 mg intravenous [IV] at week 0, 4 and 8 and 360 mg subcutaneous [SC] starting at week 12 and every 8 weeks thereafter) compared to ustekinumab (STELARA, I... |
22,137 | 2023-10-13 00:00:00 UTC | Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals | ABBV | https://www.nasdaq.com/articles/eli-lillys-lly-mirikizumab-meets-crohns-disease-study-goals | null | null | Eli Lilly LLY announced encouraging data from the phase III VIVID-1 study, which evaluated its IL-23p19 antibody mirikizumab for adult patients with moderate-to-severe Crohn’s disease (“CD”).
The VIVID-1 study achieved its co-primary and all major secondary endpoints. Mirikizumab demonstrated clinical remission and end... | If approved, Lilly will face stiff competition from AbbVie ABBV, which markets its own drug Skyrizi, which utilizes a similar mechanism of action to treat CD. A blockbuster IL-23 inhibitor, AbbVie’s Skyrizi received label expansion in the United States and Europe last year in CD indication. Last month, ABBV reported da... | Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report To read this article on Zacks.com click here. If approved, Lil... | Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report To read this article on Zacks.com click here. If approved, Lil... | Last month, ABBV reported data from a head-to-head phase III study that compared Skyrizi to J&J’s Stelara in CD indication. If approved, Lilly will face stiff competition from AbbVie ABBV, which markets its own drug Skyrizi, which utilizes a similar mechanism of action to treat CD. A blockbuster IL-23 inhibitor, AbbVie... |
22,138 | 2023-10-13 00:00:00 UTC | See Which Of The Latest 13F Filers Holds AbbVie | ABBV | https://www.nasdaq.com/articles/see-which-of-the-latest-13f-filers-holds-abbvie-9 | null | null | At Holdings Channel, we have reviewed the latest batch of the 26 most recent 13F filings for the 09/30/2023 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 21 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed... | At Holdings Channel, we have reviewed the latest batch of the 26 most recent 13F filings for the 09/30/2023 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 21 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the ... | Existing -42,976 +$2,076 Radnor Capital Management LLC Existing +2,017 +$665 New Capital Management LP NEW +4,500 +$671 Brendel Financial Advisors LLC Existing -15 +$98 Granite Bay Wealth Management LLC NEW +24,255 +$3,561 Toth Financial Advisory Corp Existing -3,163 +$126 Kinneret Advisory LLC Existing -32 +$772 IFP A... | Existing -42,976 +$2,076 Radnor Capital Management LLC Existing +2,017 +$665 New Capital Management LP NEW +4,500 +$671 Brendel Financial Advisors LLC Existing -15 +$98 Granite Bay Wealth Management LLC NEW +24,255 +$3,561 Toth Financial Advisory Corp Existing -3,163 +$126 Kinneret Advisory LLC Existing -32 +$772 IFP A... | Existing -42,976 +$2,076 Radnor Capital Management LLC Existing +2,017 +$665 New Capital Management LP NEW +4,500 +$671 Brendel Financial Advisors LLC Existing -15 +$98 Granite Bay Wealth Management LLC NEW +24,255 +$3,561 Toth Financial Advisory Corp Existing -3,163 +$126 Kinneret Advisory LLC Existing -32 +$772 IFP A... |
22,139 | 2023-10-13 00:00:00 UTC | AbbVie's (ABBV) Rinvoq Meets Key Goal in Phase II Vitiligo Study | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-rinvoq-meets-key-goal-in-phase-ii-vitiligo-study | null | null | AbbVie ABBV announced positive results from its mid-stage study evaluating Rinvoq (upadacitinib) in a new indication. The phase IIb study evaluated the 6 mg, 11 mg and 22 mg dose strengths of Rinvoq in adult patients with non-segmental vitiligo (NSV) compared with placebo.
The study met its primary endpoint of the perc... | AbbVie ABBV announced positive results from its mid-stage study evaluating Rinvoq (upadacitinib) in a new indication. Per AbbVie, vitiligo affects approximately 2% of the global population and takes a serious toll on the patient’s quality of life. Based on the positive results from the phase IIb vitiligo study, AbbVie ... | Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report To read this article on Zacks.com click here. Ab... | AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote Zacks Rank and Stocks to Consider AbbVie currently has a Zacks Rank #3 (Hold). Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report A... | AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote Zacks Rank and Stocks to Consider AbbVie currently has a Zacks Rank #3 (Hold). AbbVie ABBV announced positive results from its mid-stage study evaluating Rinvoq (upadacitinib) in a new indication. Per AbbVie, vitiligo affects approxim... |
22,140 | 2023-10-13 00:00:00 UTC | ABBV Stock: Buy for the Yield, Hold for This Other Reason | ABBV | https://www.nasdaq.com/articles/abbv-stock%3A-buy-for-the-yield-hold-for-this-other-reason | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
From late spring through much of the summer, AbbVie (NYSE:ABBV) stock encountered a fair bit of turbulence.
With sales of the big pharma firm’s flagship drug Humira dropping, investors bailed on ABBV stock, fearful of continued poor results ahead.
However, ... | With sales of the big pharma firm’s flagship drug Humira dropping, investors bailed on ABBV stock, fearful of continued poor results ahead. A Key Reason to Make This a Long-Term Hold If high interest rates and a 2024 recession result in a stormy market once again, ABBV stock could provide you with consistent gains from... | ABBV Stock: Addressing Value Trap Concerns Since the aforementioned Q2 earnings release, AbbVie shares have bounced back from the $130s per share back to around $150 per share, with the stock holding steady near this price level for the past two months. If, like last quarter, AbbVie can show that rising sales of drugs ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips From late spring through much of the summer, AbbVie (NYSE:ABBV) stock encountered a fair bit of turbulence. ABBV Stock: Addressing Value Trap Concerns Since the aforementioned Q2 earnings release, AbbVie shares have bounced back from the $130s per share bac... | However, since the release of AbbVie’s Q2 2023 results back in July, investor sentiment for this stock has improved. ABBV Stock: Addressing Value Trap Concerns Since the aforementioned Q2 earnings release, AbbVie shares have bounced back from the $130s per share back to around $150 per share, with the stock holding ste... |
22,141 | 2023-10-12 00:00:00 UTC | AbbVie: Upadacitinib Phase 2b Study In Non-segmental Vitiligo Meets Primary Goal | ABBV | https://www.nasdaq.com/articles/abbvie%3A-upadacitinib-phase-2b-study-in-non-segmental-vitiligo-meets-primary-goal | null | null | (RTTNews) - AbbVie (ABBV) announced Thursday that its Phase 2b study evaluating upadacitinib (RINVOQ) in adults with non-segmental vitiligo or NSV met the primary endpoint. Based on the data, the company is advancing its clinical program of upadacitinib in vitiligo to Phase 3.
NSV is the most common form of vitiligo, a... | (RTTNews) - AbbVie (ABBV) announced Thursday that its Phase 2b study evaluating upadacitinib (RINVOQ) in adults with non-segmental vitiligo or NSV met the primary endpoint. Based on the data, the company is advancing its clinical program of upadacitinib in vitiligo to Phase 3. NSV is the most common form of vitiligo, a... | (RTTNews) - AbbVie (ABBV) announced Thursday that its Phase 2b study evaluating upadacitinib (RINVOQ) in adults with non-segmental vitiligo or NSV met the primary endpoint. Based on the data, the company is advancing its clinical program of upadacitinib in vitiligo to Phase 3. In the trial, upadacitinib at week 24 met ... | (RTTNews) - AbbVie (ABBV) announced Thursday that its Phase 2b study evaluating upadacitinib (RINVOQ) in adults with non-segmental vitiligo or NSV met the primary endpoint. In the trial, upadacitinib at week 24 met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index or F-VASI with... | (RTTNews) - AbbVie (ABBV) announced Thursday that its Phase 2b study evaluating upadacitinib (RINVOQ) in adults with non-segmental vitiligo or NSV met the primary endpoint. Based on the data, the company is advancing its clinical program of upadacitinib in vitiligo to Phase 3. In the trial, upadacitinib at week 24 met ... |
22,142 | 2023-10-12 00:00:00 UTC | Billionaire Paul Tudor Jones Predicts a Recession in Early 2024. Here's What It Could Mean for Stocks. | ABBV | https://www.nasdaq.com/articles/billionaire-paul-tudor-jones-predicts-a-recession-in-early-2024.-heres-what-it-could-mean | null | null | Paul Tudor Jones II built a fortune currently worth over $8 billion. Much of his success is due to shrewd trades on currencies and interest rate moves. His Tudor Investment hedge fund is also heavily invested in stocks, with more than 50 equity positions, in addition to several call and put options on individual stocks... | For example, AbbVie (NYSE: ABBV) tends to hold up well during a recession or when the overall market declines. AbbVie is cheap right now, with its shares trading at a forward earnings multiple of only 13.6x. Keith Speights has positions in AbbVie, Bank of America, and Berkshire Hathaway. | For example, AbbVie (NYSE: ABBV) tends to hold up well during a recession or when the overall market declines. AbbVie is cheap right now, with its shares trading at a forward earnings multiple of only 13.6x. Keith Speights has positions in AbbVie, Bank of America, and Berkshire Hathaway. | For example, AbbVie (NYSE: ABBV) tends to hold up well during a recession or when the overall market declines. AbbVie is cheap right now, with its shares trading at a forward earnings multiple of only 13.6x. Keith Speights has positions in AbbVie, Bank of America, and Berkshire Hathaway. | For example, AbbVie (NYSE: ABBV) tends to hold up well during a recession or when the overall market declines. AbbVie is cheap right now, with its shares trading at a forward earnings multiple of only 13.6x. Keith Speights has positions in AbbVie, Bank of America, and Berkshire Hathaway. |
22,143 | 2023-10-12 00:00:00 UTC | Morgan Stanley Maintains Abbvie (ABBV) Overweight Recommendation | ABBV | https://www.nasdaq.com/articles/morgan-stanley-maintains-abbvie-abbv-overweight-recommendation-1 | null | null | Fintel reports that on October 11, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation.
Analyst Price Forecast Suggests 16.05% Upside
As of October 5, 2023, the average one-year price target for Abbvie is 173.32. The forecasts range from a low of 136.35 to a high of $215.25. ... | AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Fintel reports that on October 11, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 16.0... | Fintel reports that on October 11, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 16.05% Upside As of October 5, 2023, the average one-year price target for Abbvie is 173.32. The projected annual revenue for Abbvie is 55,229MM, a decrease... | Abbvie Declares $1.48 Dividend On September 8, 2023 the company declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). Fintel reports that on October 11, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 16.05% Upside A... | Fintel reports that on October 11, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 16.05% Upside As of October 5, 2023, the average one-year price target for Abbvie is 173.32. The projected annual revenue for Abbvie is 55,229MM, a decrease... |
22,144 | 2023-10-11 00:00:00 UTC | XLV, ABBV, TMO, PFE: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/xlv-abbv-tmo-pfe%3A-large-outflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $203.2 million dollar outflow -- that's a 0.5% decrease week over week (from 294,570,000 to 293,02... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.5%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.4%, and Pfizer Inc (Symbol: PFE) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered a... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.5%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.4%, and Pfizer Inc (Symbol: PFE) is lower by about 0.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one ye... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.5%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.4%, and Pfizer Inc (Symbol: PFE) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered a... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.5%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.4%, and Pfizer Inc (Symbol: PFE) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered a... |
22,145 | 2023-10-11 00:00:00 UTC | AbbVie: Three Ongoing Phase 3 Studies Show Long-term Efficacy Of RINVOQ | ABBV | https://www.nasdaq.com/articles/abbvie%3A-three-ongoing-phase-3-studies-show-long-term-efficacy-of-rinvoq | null | null | (RTTNews) - AbbVie (ABBV) reported new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further showed the long-term efficacy and safety profile of RINVOQ among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks.
In the Measure Up 1, Mea... | (RTTNews) - AbbVie (ABBV) reported new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further showed the long-term efficacy and safety profile of RINVOQ among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks. In the Measure Up 1, Mea... | (RTTNews) - AbbVie (ABBV) reported new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further showed the long-term efficacy and safety profile of RINVOQ among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks. In the Measure Up 1, Mea... | (RTTNews) - AbbVie (ABBV) reported new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further showed the long-term efficacy and safety profile of RINVOQ among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks. In the Measure Up 1, Mea... | (RTTNews) - AbbVie (ABBV) reported new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further showed the long-term efficacy and safety profile of RINVOQ among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks. In the Measure Up 1, Mea... |
22,146 | 2023-10-11 00:00:00 UTC | 3 Absurdly Cheap Dividend Stocks to Buy and Hold for Years | ABBV | https://www.nasdaq.com/articles/3-absurdly-cheap-dividend-stocks-to-buy-and-hold-for-years | null | null | A good way to maximize your potential returns is by focusing on cheap stocks that also pay dividends. That way, you collect a recurring payout while also setting yourself up for some attractive profits down the road. Three stocks that tick off both checkmarks for investors are Verizon Communications (NYSE: VZ), Cisco S... | Investors are hesitant to buy shares of the company as AbbVie expects its top drug, Humira, to see a drop of 35% in revenue this year due to an increase in competition with several biosimilars becoming available and providing patients with cheaper options. Three stocks that tick off both checkmarks for investors are Ve... | Three stocks that tick off both checkmarks for investors are Verizon Communications (NYSE: VZ), Cisco Systems (NASDAQ: CSCO), and AbbVie (NYSE: ABBV). While its payout ratio may seem high at over 100%, that's not indicative of the dividend's safety, as over the trailing 12 months AbbVie has generated free cash flow of ... | Three stocks that tick off both checkmarks for investors are Verizon Communications (NYSE: VZ), Cisco Systems (NASDAQ: CSCO), and AbbVie (NYSE: ABBV). AbbVie A third high-yielding dividend stock that looks cheap right now is AbbVie. Investors are hesitant to buy shares of the company as AbbVie expects its top drug, Hum... | Three stocks that tick off both checkmarks for investors are Verizon Communications (NYSE: VZ), Cisco Systems (NASDAQ: CSCO), and AbbVie (NYSE: ABBV). AbbVie A third high-yielding dividend stock that looks cheap right now is AbbVie. Investors are hesitant to buy shares of the company as AbbVie expects its top drug, Hum... |
22,147 | 2023-10-11 00:00:00 UTC | The 3 Best Defensive Stocks for Nervous Investors | ABBV | https://www.nasdaq.com/articles/the-3-best-defensive-stocks-for-nervous-investors | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Nervous investors are turning to defensive stocks, and there’s plenty of reason to be among their ranks. The U.S. Federal Reserve’s continuing battle to control inflation is the primary reason catalyzing increasing nervousness. A few weeks ago, the Fed sign... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) shares are relatively inexpensive at the moment. Generally speaking, defensive investors are likely to be attracted to ABBV shares simply because the company is a well-known healthcare firm and healthcare stocks are defensive in nature. Beyo... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) shares are relatively inexpensive at the moment. Generally speaking, defensive investors are likely to be attracted to ABBV shares simply because the company is a well-known healthcare firm and healthcare stocks are defensive in nature. Beyo... | Generally speaking, defensive investors are likely to be attracted to ABBV shares simply because the company is a well-known healthcare firm and healthcare stocks are defensive in nature. AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) shares are relatively inexpensive at the moment. Beyo... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) shares are relatively inexpensive at the moment. Generally speaking, defensive investors are likely to be attracted to ABBV shares simply because the company is a well-known healthcare firm and healthcare stocks are defensive in nature. Beyo... |
22,148 | 2023-10-10 00:00:00 UTC | Ex-Dividend Reminder: American Eagle Outfitters, Foot Locker and AbbVie | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-american-eagle-outfitters-foot-locker-and-abbvie | null | null | Looking at the universe of stocks we cover at Dividend Channel, on 10/12/23, American Eagle Outfitters, Inc. (Symbol: AEO), Foot Locker, Inc. (Symbol: FL), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. American Eagle Outfitters, Inc. will pay its quarterly dividend of... | If they do continue, the current estimated yields on annualized basis would be 2.38% for American Eagle Outfitters, Inc., 7.71% for Foot Locker, Inc., and 3.97% for AbbVie Inc. Looking at the universe of stocks we cover at Dividend Channel, on 10/12/23, American Eagle Outfitters, Inc. (Symbol: AEO), Foot Locker, Inc. (... | Looking at the universe of stocks we cover at Dividend Channel, on 10/12/23, American Eagle Outfitters, Inc. (Symbol: AEO), Foot Locker, Inc. (Symbol: FL), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. American Eagle Outfitters, Inc. will pay its quarterly dividend of... | Looking at the universe of stocks we cover at Dividend Channel, on 10/12/23, American Eagle Outfitters, Inc. (Symbol: AEO), Foot Locker, Inc. (Symbol: FL), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. American Eagle Outfitters, Inc. will pay its quarterly dividend of... | If they do continue, the current estimated yields on annualized basis would be 2.38% for American Eagle Outfitters, Inc., 7.71% for Foot Locker, Inc., and 3.97% for AbbVie Inc. Looking at the universe of stocks we cover at Dividend Channel, on 10/12/23, American Eagle Outfitters, Inc. (Symbol: AEO), Foot Locker, Inc. (... |
22,149 | 2023-10-10 00:00:00 UTC | 3 Dividend Kings Every Investor Should Own to Survive a Market Crash | ABBV | https://www.nasdaq.com/articles/3-dividend-kings-every-investor-should-own-to-survive-a-market-crash | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Dividend stocks have proved time and again to be a superior investing strategy. We all want capital appreciation, or to see our stocks grow in value over time, but dividends are what really drive excess returns.
Analysts at JPMorgan Chase (NYSE:JPM) studied... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Pharmaceutical stock AbbVie (NYSE:ABBV) isn’t your typical Dividend King. Still, AbbVie began paying a dividend upon its separation in 2013 and immediately began raising it every year thereafter. AbbVie generates most of its revenue from arthritis therapy Humi... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Pharmaceutical stock AbbVie (NYSE:ABBV) isn’t your typical Dividend King. Still, AbbVie began paying a dividend upon its separation in 2013 and immediately began raising it every year thereafter. AbbVie generates most of its revenue from arthritis therapy Humi... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Pharmaceutical stock AbbVie (NYSE:ABBV) isn’t your typical Dividend King. Still, AbbVie began paying a dividend upon its separation in 2013 and immediately began raising it every year thereafter. AbbVie generates most of its revenue from arthritis therapy Humi... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Pharmaceutical stock AbbVie (NYSE:ABBV) isn’t your typical Dividend King. Still, AbbVie began paying a dividend upon its separation in 2013 and immediately began raising it every year thereafter. AbbVie generates most of its revenue from arthritis therapy Humi... |
22,150 | 2023-10-10 00:00:00 UTC | Three Stocks To Help You Through the Financial Roller Coaster! | ABBV | https://www.nasdaq.com/articles/three-stocks-to-help-you-through-the-financial-roller-coaster | null | null | The world's eyes are on the Middle East again during one of the darkest hours of the region. Tensions broke into declarations of armed conflict as Hamas, the militant group that holds the Gaza Strip, launched an unprecedented attack on Israel, with the latter promising “significant military steps” as retaliation. This ... | AbbVie Inc. (ABBV) AbbVie Inc. is a research-based biopharmaceutical company that researches, develops, and manufactures various medicines. ABBV’s dividend yield is currently at 3.92%, with a dividend payout ratio of 45.36% and a 120.31% 5-year dividend growth rate. AbbVie has consistently increased its dividends for 5... | Analyst Ratings Analysts rate ABBV as a "Moderate Buy" based on 7 Strong buys, 2 Moderate buys, and 8 Hold recommendations from analysts. AbbVie Inc. (ABBV) AbbVie Inc. is a research-based biopharmaceutical company that researches, develops, and manufactures various medicines. ABBV’s dividend yield is currently at 3.92... | ABBV’s dividend yield is currently at 3.92%, with a dividend payout ratio of 45.36% and a 120.31% 5-year dividend growth rate. Analyst Ratings Analysts rate ABBV as a "Moderate Buy" based on 7 Strong buys, 2 Moderate buys, and 8 Hold recommendations from analysts. AbbVie Inc. (ABBV) AbbVie Inc. is a research-based biop... | ABBV’s dividend yield is currently at 3.92%, with a dividend payout ratio of 45.36% and a 120.31% 5-year dividend growth rate. AbbVie Inc. (ABBV) AbbVie Inc. is a research-based biopharmaceutical company that researches, develops, and manufactures various medicines. AbbVie has consistently increased its dividends for 5... |
22,151 | 2023-10-09 00:00:00 UTC | 2 Magnificent Dividend Stocks to Buy Hand Over Fist in October | ABBV | https://www.nasdaq.com/articles/2-magnificent-dividend-stocks-to-buy-hand-over-fist-in-october | null | null | Investing in stocks may not look particularly appealing at the moment, given that the 10-year U.S. Treasury bond is offering a near 5% annualized yield. After all, most stocks outside the areas of artificial intelligence and weight-loss care have lost ground over the last two years because of various economic and geopo... | Biotech heavyweights AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) are both working through a multiyear portfolio churn, but their proven ability to maintain a strong competitive edge through industry-leading levels of innovation should comfort anxious investors. That may not be the most convincing outlook for a dividen... | Biotech heavyweights AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) are both working through a multiyear portfolio churn, but their proven ability to maintain a strong competitive edge through industry-leading levels of innovation should comfort anxious investors. AbbVie: A 3.99% yield AbbVie is a dividend powerhouse. As... | That may not be the most convincing outlook for a dividend stock (analysts usually prefer a competitive advantage that lasts for at least 20 years), but it should be enough to make AbbVie's shares a valuable part of a diversified income portfolio. Biotech heavyweights AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) are bo... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! Biotech heavyweights AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) are both working through a multiyear portfolio churn, but their proven ability to maintain a strong competitive edge through i... |
22,152 | 2023-10-09 00:00:00 UTC | GCOW: An ETF for Dividend and Free Cash Flow Lovers | ABBV | https://www.nasdaq.com/articles/gcow%3A-an-etf-for-dividend-and-free-cash-flow-lovers | null | null | The Pacer Global Cash Cows Dividend ETF (BATS:GCOW) offers investors a nice mix of domestic and international companies that generate strong free cash flows, and it sports an attractive 5.9% dividend yield. Let’s take a deeper dive into this $1.6 billion ETF from Pacer and find out whether it’s an attractive opportunit... | Beyond energy, GCOW owns healthcare names like AbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN), and Sanofi (NASDAQ:SNY). However, after running these screens, GCOW’s portfolio of holdings had a much cheaper price-to-earnings ratio of 6.8 times earnings and much higher free cash flow and dividend yields of 8.0% and 5.7%, respec... | Beyond energy, GCOW owns healthcare names like AbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN), and Sanofi (NASDAQ:SNY). The Pacer Global Cash Cows Dividend ETF (BATS:GCOW) offers investors a nice mix of domestic and international companies that generate strong free cash flows, and it sports an attractive 5.9% dividend yield. ... | Beyond energy, GCOW owns healthcare names like AbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN), and Sanofi (NASDAQ:SNY). GCOW seeks to deliver both income and capital appreciation by investing in companies with high free cash flow yields and high dividend yields. Pacer explains that focusing on companies with high free cash fl... | Beyond energy, GCOW owns healthcare names like AbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN), and Sanofi (NASDAQ:SNY). GCOW is part of the popular Pacer Cash Cows Index ETF Series, all of which take slightly different approaches to investing in stocks with high free cash flow yields. Assuming that the expense ratio remains a... |
22,153 | 2023-10-09 00:00:00 UTC | AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-rises-yet-lags-behind-market%3A-some-facts-worth-knowing | null | null | AbbVie (ABBV) closed the latest trading day at $149.11, indicating a +0.59% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.63%. Meanwhile, the Dow experienced a rise of 0.59%, and the technology-dominated Nasdaq saw an increase of 0.39%.
The drugmaker's shares hav... | AbbVie (ABBV) closed the latest trading day at $149.11, indicating a +0.59% change from the previous session's end. The investment community will be closely monitoring the performance of AbbVie in its forthcoming earnings report. It is also important to note the recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed the latest trading day at $149.11, indicating a +0.59% change from the previous session's end. The investment community will be closely monitoring the performance of AbbVie in its forthcoming earnings report. It is also important to note the recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed the latest trading day at $149.11, indicating a +0.59% change from the previous session's end. The investment community will be closely monitoring the performance of AbbVie in its forthcoming earnings report. It is also important to note the recent changes to analyst estimates for AbbVie. | The investment community will be closely monitoring the performance of AbbVie in its forthcoming earnings report. AbbVie (ABBV) closed the latest trading day at $149.11, indicating a +0.59% change from the previous session's end. It is also important to note the recent changes to analyst estimates for AbbVie. |
22,154 | 2023-10-06 00:00:00 UTC | AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-buys-parkinsons-disease-treatment-maker | null | null | AbbVie ABBV announced that it is exercising its exclusive right and acquiring private biotech company Mitokinin, which is making a novel treatment for Parkinson's Disease (“PD”).
Mitokinin’s lead pipeline compound is a selective PINK1 activator that addresses mitochondrial dysfunction, which plays an instrumental role ... | AbbVie ABBV announced that it is exercising its exclusive right and acquiring private biotech company Mitokinin, which is making a novel treatment for Parkinson's Disease (“PD”). In March this year, the FDA issued a complete response letter (CRL) to AbbVie’s new drug application (“NDA”) seeking approval for ABBV-951. Y... | AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote Some top-ranked drug/biotech companies worth considering are Alpine Immune Sciences ALPN, Aurinia Pharmaceuticals AUPH and Corcept Therapeutics CORT, each carrying a Zacks Rank #2 (Buy) at present. Click to get this free report AbbVie... | AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote Some top-ranked drug/biotech companies worth considering are Alpine Immune Sciences ALPN, Aurinia Pharmaceuticals AUPH and Corcept Therapeutics CORT, each carrying a Zacks Rank #2 (Buy) at present. Click to get this free report AbbVie... | AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote Some top-ranked drug/biotech companies worth considering are Alpine Immune Sciences ALPN, Aurinia Pharmaceuticals AUPH and Corcept Therapeutics CORT, each carrying a Zacks Rank #2 (Buy) at present. AbbVie ABBV announced that it is exe... |
22,155 | 2023-10-06 00:00:00 UTC | Should You Load Up On This 1 Dividend Stock? | ABBV | https://www.nasdaq.com/articles/should-you-load-up-on-this-1-dividend-stock | null | null | There are excellent reasons to invest in dividend stocks beyond their regular payouts. Growing a dividend requires companies to deliver solid financial results regularly, and the longer a corporation can keep things going, the more it says about the strength of its operations. Furthermore, investors who choose to reinv... | Handling its biggest headwind Naysayers will quickly mention that AbbVie now faces generic competition in the U.S. for its best-selling medicine, arthritis therapy Humira. The fact that AbbVie found a way to replace its earnings, albeit with two drugs, is just more evidence of the company's ability to continue developi... | So, despite facing generic competition for Humira, AbbVie is far from dead in the water. But one that looks attractive right now is drugmaker AbbVie (NYSE: ABBV). AbbVie's stellar dividend history AbbVie was once a division of the medical device giant Abbott Laboratories. | AbbVie's stellar dividend history AbbVie was once a division of the medical device giant Abbott Laboratories. Income-seekers need not look elsewhere While no one can precisely predict the future, AbbVie's excellent dividend history and robust business strongly suggest that the company is unlikely to suspend its payouts... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! But one that looks attractive right now is drugmaker AbbVie (NYSE: ABBV). AbbVie's stellar dividend history AbbVie was once a division of the medical device giant Abbott Laboratories. |
22,156 | 2023-10-06 00:00:00 UTC | Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-lly-offers-to-buy-point-biopharma-other-updates | null | null | This week, Eli Lilly LLY announced a deal to take over POINT Biopharma for approximately $1.4 billion. Sanofi SNY in-licensed co-development and commercialization rights to Teva’s immunology candidate. Novartis NVS announced positive top-line data from a late-stage study on pipeline candidate iptacopan in patients with... | AstraZeneca AZN settled its product liability litigation related to its heartburn drugs, Nexium and Prilosec, for $425 million.AbbVie ABBV announced that it is buying a private Parkinson’s disease drug developer, Mitokinin. AbbVie Buys Private Parkinson’s Disease Drug Developer: AbbVie announced that it has exercised i... | AstraZeneca AZN settled its product liability litigation related to its heartburn drugs, Nexium and Prilosec, for $425 million.AbbVie ABBV announced that it is buying a private Parkinson’s disease drug developer, Mitokinin. For the deal, AbbVie is making a payment of $110 million while Mitokinin shareholders will remai... | For the deal, AbbVie is making a payment of $110 million while Mitokinin shareholders will remain eligible for potential development/commercial milestone payments of up to $545 million Novartis Iptacopan Phase III IgAN Study Meets Primary Goal: Novartis’s phase III APPLAUSE study evaluating iptacopan in patients with ... | For the deal, AbbVie is making a payment of $110 million while Mitokinin shareholders will remain eligible for potential development/commercial milestone payments of up to $545 million Novartis Iptacopan Phase III IgAN Study Meets Primary Goal: Novartis’s phase III APPLAUSE study evaluating iptacopan in patients with ... |
22,157 | 2023-10-05 00:00:00 UTC | Retirement Royalty: 3 Dividend Aristocrats for a Steady Income Stream | ABBV | https://www.nasdaq.com/articles/retirement-royalty%3A-3-dividend-aristocrats-for-a-steady-income-stream | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Dividend investing will always stay in style. While the market moves in cycles of ups and downs, dividend investing offers income even during prolonged market downturns. This reliable income has garnered the interest and love of most long-term investors due... | ABBV also announced positive Phase 3 topline results on the second set of its three-phase trial for its BOTOX® Cosmetic as a treatment for the disruption on the neck, jawline, and lower face attributed to platysma prominence. AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie Inc. (NYSE:ABBV) is a bioph... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie Inc. (NYSE:ABBV) is a biopharmaceutical company specializing in various therapeutic products in immunology, oncology, aesthetics, and neuroscience. ABBV also announced positive Phase 3 topline results on the second set of its three-phase trial for its B... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie Inc. (NYSE:ABBV) is a biopharmaceutical company specializing in various therapeutic products in immunology, oncology, aesthetics, and neuroscience. ABBV also announced positive Phase 3 topline results on the second set of its three-phase trial for its B... | With a strong portfolio of upcoming products and dividend history, ABBV is an excellent choice for dividend stocks to buy for retirement. AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie Inc. (NYSE:ABBV) is a biopharmaceutical company specializing in various therapeutic products in immunology, oncolog... |
22,158 | 2023-10-04 00:00:00 UTC | 7 Top Healthcare Stocks That Pay Dividends | ABBV | https://www.nasdaq.com/articles/7-top-healthcare-stocks-that-pay-dividends | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Facing an uncertain market environment, investors ought to consider the top healthcare stocks that pay dividends. Sure, the Federal Reserve may be in a position to facilitate a soft landing for the economy, per bullish analysts. Genuinely, I hope that’s the... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com A pharmaceutical giant, AbbVie (NYSE:ABBV) commands a diverse lineup of products for diseases. In particular, I’m fascinated with the Allergan buyout, which gives AbbVie control over Botox. Financially, ABBV symbolizes one of the top healthcare stocks that pay... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com A pharmaceutical giant, AbbVie (NYSE:ABBV) commands a diverse lineup of products for diseases. In particular, I’m fascinated with the Allergan buyout, which gives AbbVie control over Botox. Financially, ABBV symbolizes one of the top healthcare stocks that pay... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com A pharmaceutical giant, AbbVie (NYSE:ABBV) commands a diverse lineup of products for diseases. In particular, I’m fascinated with the Allergan buyout, which gives AbbVie control over Botox. Financially, ABBV symbolizes one of the top healthcare stocks that pay... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com A pharmaceutical giant, AbbVie (NYSE:ABBV) commands a diverse lineup of products for diseases. In particular, I’m fascinated with the Allergan buyout, which gives AbbVie control over Botox. Financially, ABBV symbolizes one of the top healthcare stocks that pay... |
22,159 | 2023-10-04 00:00:00 UTC | 3 High-Yielding Dividend Growth Stocks That Have Increased Their Payouts by 50% in 5 Years | ABBV | https://www.nasdaq.com/articles/3-high-yielding-dividend-growth-stocks-that-have-increased-their-payouts-by-50-in-5-years | null | null | If you're investing in a dividend stock, there's more than just the yield and the payout ratio to consider. It's also important to look at dividend increases -- whether the company has been making them in the past and is likely to continue doing so in the future. That's because if dividend payments grow, you'll be coll... | With a broad business that includes eye care products, neuroscience, aesthetics (it owns Botox), and some fast-growing immunology drugs in Skyrizi and Rinvoq, AbbVie stock makes for a potential steal of a deal for income investors as it's trading at only 14 times its estimated future earnings -- the healthcare average ... | Three great dividend growth stocks to consider owning right now are AbbVie (NYSE: ABBV), McDonald's (NYSE: MCD), and Comcast (NASDAQ: CMCSA). With a broad business that includes eye care products, neuroscience, aesthetics (it owns Botox), and some fast-growing immunology drugs in Skyrizi and Rinvoq, AbbVie stock makes ... | When including its time as a part of Abbott Laboratories (AbbVie spun off in 2013), it's technically a Dividend King, having increased its dividend payments for 50-plus years. Over the trailing 12 months, AbbVie has generated free cash flow of $24.8 billion, which is easily more than enough to cover the $10.3 billion i... | At 2.3%, it's not as high of a payout as AbbVie, but it's also a fantastic income investment; McDonald's has increased its dividend payments for 46 straight years, and another hike could be coming this next month to push that streak even further. Three great dividend growth stocks to consider owning right now are AbbVi... |
22,160 | 2023-10-03 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-119 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Get the latest Zacks research report on ABBV — FREE Get the latest Zacks research report on CAH — FREE Dividend Growth Stocks: 25 Aristocrats » Also see: Funds Holding QSG Institutional Holders of DIM BSCQ market cap history The views and opinions expressed herein are the views and opinions of the author and do n... | Sherwin-Williams Co (Symbol: SHW) $252.65 $304.39 20.48% RLI Corp (Symbol: RLI) $134.02 $159.50 19.01% Dover Corp (Symbol: DOV) $137.68 $163.17 18.51% AbbVie Inc (Symbol: ABBV) $148.25 $173.31 16.90% Cardinal Health, Inc. (Symbol: CAH) $86.38 $95.50 10.56% The average 12-month analyst targets are only targets for the s... | Sherwin-Williams Co (Symbol: SHW) $252.65 $304.39 20.48% RLI Corp (Symbol: RLI) $134.02 $159.50 19.01% Dover Corp (Symbol: DOV) $137.68 $163.17 18.51% AbbVie Inc (Symbol: ABBV) $148.25 $173.31 16.90% Cardinal Health, Inc. (Symbol: CAH) $86.38 $95.50 10.56% The average 12-month analyst targets are only targets for the s... | Sherwin-Williams Co (Symbol: SHW) $252.65 $304.39 20.48% RLI Corp (Symbol: RLI) $134.02 $159.50 19.01% Dover Corp (Symbol: DOV) $137.68 $163.17 18.51% AbbVie Inc (Symbol: ABBV) $148.25 $173.31 16.90% Cardinal Health, Inc. (Symbol: CAH) $86.38 $95.50 10.56% The average 12-month analyst targets are only targets for the s... |
22,161 | 2023-10-02 00:00:00 UTC | SPHQ, V, ABBV, MRK: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/sphq-v-abbv-mrk%3A-large-inflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500— Quality ETF (Symbol: SPHQ) where we have detected an approximate $84.1 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 116,410,000 ... | Among the largest underlying components of SPHQ, in trading today Visa Inc (Symbol: V) is trading flat, AbbVie Inc (Symbol: ABBV) is down about 0.5%, and Merck & Co Inc (Symbol: MRK) is lower by about 0.5%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodat... | Among the largest underlying components of SPHQ, in trading today Visa Inc (Symbol: V) is trading flat, AbbVie Inc (Symbol: ABBV) is down about 0.5%, and Merck & Co Inc (Symbol: MRK) is lower by about 0.5%. For a complete list of holdings, visit the SPHQ Holdings page » The chart below shows the one year price performa... | Among the largest underlying components of SPHQ, in trading today Visa Inc (Symbol: V) is trading flat, AbbVie Inc (Symbol: ABBV) is down about 0.5%, and Merck & Co Inc (Symbol: MRK) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one... | Among the largest underlying components of SPHQ, in trading today Visa Inc (Symbol: V) is trading flat, AbbVie Inc (Symbol: ABBV) is down about 0.5%, and Merck & Co Inc (Symbol: MRK) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one... |
22,162 | 2023-10-02 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-12 | null | null | AbbVie (ABBV) closed the most recent trading day at $148.25, moving -0.54% from the previous trading session. This change lagged the S&P 500's daily gain of 0.01%. At the same time, the Dow lost 0.22%, and the tech-heavy Nasdaq gained 0.67%.
Coming into today, shares of the drugmaker had gained 0.58% in the past month.... | AbbVie (ABBV) closed the most recent trading day at $148.25, moving -0.54% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. On that day, AbbVie is projected to report earnings of $2.87 per share, which would represent a year-over-year decline of 21.58%... | AbbVie (ABBV) closed the most recent trading day at $148.25, moving -0.54% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. On that day, AbbVie is projected to report earnings of $2.87 per share, which would represent a year-over-year decline of 21.58%... | AbbVie (ABBV) closed the most recent trading day at $148.25, moving -0.54% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. On that day, AbbVie is projected to report earnings of $2.87 per share, which would represent a year-over-year decline of 21.58%... | AbbVie (ABBV) closed the most recent trading day at $148.25, moving -0.54% from the previous trading session. On that day, AbbVie is projected to report earnings of $2.87 per share, which would represent a year-over-year decline of 21.58%. AbbVie will be looking to display strength as it nears its next earnings release... |
22,163 | 2023-10-02 00:00:00 UTC | Boehringer launches unbranded Humira biosimilar at 81% discount | ABBV | https://www.nasdaq.com/articles/boehringer-launches-unbranded-humira-biosimilar-at-81-discount-0 | null | null | By Mariam Sunny and Patrick Wingrove
Oct 2 (Reuters) - Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar of AbbVie's ABBV.N Humira with a list price 81% cheaper than the blockbuster rheumatoid arthritis drug.
The company in July launched a branded biosimilar, Cyltezo, priced at a ... | By Mariam Sunny and Patrick Wingrove Oct 2 (Reuters) - Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar of AbbVie's ABBV.N Humira with a list price 81% cheaper than the blockbuster rheumatoid arthritis drug. Unlike easy to manufacture pills that can be copied and sold as generics... | By Mariam Sunny and Patrick Wingrove Oct 2 (Reuters) - Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar of AbbVie's ABBV.N Humira with a list price 81% cheaper than the blockbuster rheumatoid arthritis drug. The company in July launched a branded biosimilar, Cyltezo, priced at a ... | By Mariam Sunny and Patrick Wingrove Oct 2 (Reuters) - Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar of AbbVie's ABBV.N Humira with a list price 81% cheaper than the blockbuster rheumatoid arthritis drug. The company in July launched a branded biosimilar, Cyltezo, priced at a ... | By Mariam Sunny and Patrick Wingrove Oct 2 (Reuters) - Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar of AbbVie's ABBV.N Humira with a list price 81% cheaper than the blockbuster rheumatoid arthritis drug. The company in July launched a branded biosimilar, Cyltezo, priced at a ... |
22,164 | 2023-10-02 00:00:00 UTC | Analysts Anticipate NOBL Will Reach $102 | ABBV | https://www.nasdaq.com/articles/analysts-anticipate-nobl-will-reach-%24102 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares S&P 500 Dividend Aris... | ProShares S&P 500 Dividend Aristocrats ETF NOBL $88.55 $102.12 15.33% Cincinnati Financial Corp. CINF $102.29 $119.67 16.99% AbbVie Inc ABBV $149.06 $173.31 16.27% Procter & Gamble Company PG $145.86 $169.25 16.04% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12... | Three of NOBL's underlying holdings with notable upside to their analyst target prices are Cincinnati Financial Corp. (Symbol: CINF), AbbVie Inc (Symbol: ABBV), and Procter & Gamble Company (Symbol: PG). Similarly, ABBV has 16.27% upside from the recent share price of $149.06 if the average analyst target price of $173... | Similarly, ABBV has 16.27% upside from the recent share price of $149.06 if the average analyst target price of $173.31/share is reached, and analysts on average are expecting PG to reach a target price of $169.25/share, which is 16.04% above the recent price of $145.86. Three of NOBL's underlying holdings with notable... | ProShares S&P 500 Dividend Aristocrats ETF NOBL $88.55 $102.12 15.33% Cincinnati Financial Corp. CINF $102.29 $119.67 16.99% AbbVie Inc ABBV $149.06 $173.31 16.27% Procter & Gamble Company PG $145.86 $169.25 16.04% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12... |
22,165 | 2023-10-02 00:00:00 UTC | Drugmakers sign on to negotiate Medicare prices under protest | ABBV | https://www.nasdaq.com/articles/drugmakers-sign-on-to-negotiate-medicare-prices-under-protest | null | null | By Michael Erman and Patrick Wingrove
Oct 2 (Reuters) - All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen AMGN.O and Novartis NOVN.S, said they signed on to participate in the talks by the Oct. 1 deadline.
The pe... | The drugs involved in the first round of price talks are: blood thinner Eliquis from Bristol Myers Squibb BMY.N and Pfizer PFE.N; Merck & Co's MRK.N diabetes drug Januvia; Eliquis rival Xarelto as well as arthritis and Crohn's disease medicine Stelara from Johnson & Johnson JNJ.N; AbbVie's ABBV.N leukemia treatment Imb... | The drugs involved in the first round of price talks are: blood thinner Eliquis from Bristol Myers Squibb BMY.N and Pfizer PFE.N; Merck & Co's MRK.N diabetes drug Januvia; Eliquis rival Xarelto as well as arthritis and Crohn's disease medicine Stelara from Johnson & Johnson JNJ.N; AbbVie's ABBV.N leukemia treatment Imb... | The drugs involved in the first round of price talks are: blood thinner Eliquis from Bristol Myers Squibb BMY.N and Pfizer PFE.N; Merck & Co's MRK.N diabetes drug Januvia; Eliquis rival Xarelto as well as arthritis and Crohn's disease medicine Stelara from Johnson & Johnson JNJ.N; AbbVie's ABBV.N leukemia treatment Imb... | The drugs involved in the first round of price talks are: blood thinner Eliquis from Bristol Myers Squibb BMY.N and Pfizer PFE.N; Merck & Co's MRK.N diabetes drug Januvia; Eliquis rival Xarelto as well as arthritis and Crohn's disease medicine Stelara from Johnson & Johnson JNJ.N; AbbVie's ABBV.N leukemia treatment Imb... |
22,166 | 2023-10-02 00:00:00 UTC | The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-abbvie-lilly-sanofi-merck-and-jj | null | null | For Immediate Release
Chicago, IL – October 2, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie ABBV, Lilly LLY, San... | Here are highlights from Friday’s Analyst Blog: Pharma Stock Roundup: Regulatory Updates for Key Drugs This week, the European Commission granted marketing approval to AbbVie’s Tepkinly (epcoritamab) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Stocks recently featured in the blog includ... | Here are highlights from Friday’s Analyst Blog: Pharma Stock Roundup: Regulatory Updates for Key Drugs This week, the European Commission granted marketing approval to AbbVie’s Tepkinly (epcoritamab) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Click to get this free report Sanofi (SNY) ... | Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com cli... | Here are highlights from Friday’s Analyst Blog: Pharma Stock Roundup: Regulatory Updates for Key Drugs This week, the European Commission granted marketing approval to AbbVie’s Tepkinly (epcoritamab) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Stocks recently featured in the blog includ... |
22,167 | 2023-10-02 00:00:00 UTC | 3 Top Stocks to Buy in October and Hold Forever | ABBV | https://www.nasdaq.com/articles/3-top-stocks-to-buy-in-october-and-hold-forever | null | null | Healthcare in the United States is big business: Experts believe the system could generate more than $6 trillion in annual spending by 2030. That's an opportunity for investors to find the key players that can help grow a portfolio.
But there are so many companies in the sector, including those in medical devices, phar... | There are a lot of blue-chip healthcare stocks to choose from, but UnitedHealth Group (NYSE: UNH), AbbVie (NYSE: ABBV), and Pfizer (NYSE: PFE) stand out among the crowd. AbbVie won't miss Humira forever AbbVie is another pharmaceutical leader that recently lost its golden goose. AbbVie is also seeing double-digit growt... | There are a lot of blue-chip healthcare stocks to choose from, but UnitedHealth Group (NYSE: UNH), AbbVie (NYSE: ABBV), and Pfizer (NYSE: PFE) stand out among the crowd. Humira's decline could slow AbbVie's overall growth for a time, but analysts believe the company can still average 5% annual earnings growth, which co... | AbbVie is also seeing double-digit growth in smaller product segments like neuroscience (up 14% year over year) and eye care (up 15% year over year). Humira's decline could slow AbbVie's overall growth for a time, but analysts believe the company can still average 5% annual earnings growth, which could accelerate as Hu... | Humira's decline could slow AbbVie's overall growth for a time, but analysts believe the company can still average 5% annual earnings growth, which could accelerate as Humira's decline drops out of the equation. There are a lot of blue-chip healthcare stocks to choose from, but UnitedHealth Group (NYSE: UNH), AbbVie (N... |
22,168 | 2023-10-01 00:00:00 UTC | These Market Experts See a Downturn Coming: 2 Defensive Index Funds That Are Proven Moneymakers to Buy Now | ABBV | https://www.nasdaq.com/articles/these-market-experts-see-a-downturn-coming%3A-2-defensive-index-funds-that-are-proven | null | null | Inflation reached a four-decade high in 2022 and the Federal Reserve responded by raising its benchmark interest rate at its fastest pace since the 1980s. Initially, many experts cried recession as prices soared and credit conditions tightened across the economy. Some have since recanted their forecasts, but others rem... | The top five holdings in the index fund are detailed below: Eli Lilly: 7.8% UnitedHealth Group: 6.8% Merck: 4.8% AbbVie: 4.5% Thermo Fisher Scientific: 3.8% The Vanguard Health Care ETF returned 197% over the last decade, or 11.5% annually. When economists talk about business cycles, they're referring to alternating pe... | The top five holdings in the index fund are detailed below: Eli Lilly: 7.8% UnitedHealth Group: 6.8% Merck: 4.8% AbbVie: 4.5% Thermo Fisher Scientific: 3.8% The Vanguard Health Care ETF returned 197% over the last decade, or 11.5% annually. Detailed below are the three sectors that have historically performed best duri... | The top five holdings in the index fund are detailed below: Eli Lilly: 7.8% UnitedHealth Group: 6.8% Merck: 4.8% AbbVie: 4.5% Thermo Fisher Scientific: 3.8% The Vanguard Health Care ETF returned 197% over the last decade, or 11.5% annually. Detailed below are the three sectors that have historically performed best duri... | The top five holdings in the index fund are detailed below: Eli Lilly: 7.8% UnitedHealth Group: 6.8% Merck: 4.8% AbbVie: 4.5% Thermo Fisher Scientific: 3.8% The Vanguard Health Care ETF returned 197% over the last decade, or 11.5% annually. Here are the details, along with two index funds that could help investors hedg... |
22,169 | 2023-09-30 00:00:00 UTC | Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs | ABBV | https://www.nasdaq.com/articles/moonshot-medicine%3A-3-stocks-to-buy-to-bet-on-long-shot-drugs | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Clinical trials are a difficult and grueling process for companies. The FDA and other regulatory agencies require the highest possible standards in order to approve new drugs. To meet those standards, companies must spend exorbitant sums recruiting patients... | And with still no cure in sight for Alzheimer’s disease, the door is still wide open for the AbbVie treatment to demonstrate success and corner the market. AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Alzheimer’s disease remains a devastating condition with no known cure. But AbbVie (NYSE:ABBV) is triali... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Alzheimer’s disease remains a devastating condition with no known cure. But AbbVie (NYSE:ABBV) is trialing a new drug which could be a game-changer. ABBV-552 is a unique anti-Alzheimer drug different from most currently on the market. | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Alzheimer’s disease remains a devastating condition with no known cure. But AbbVie (NYSE:ABBV) is trialing a new drug which could be a game-changer. ABBV-552 is a unique anti-Alzheimer drug different from most currently on the market. | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Alzheimer’s disease remains a devastating condition with no known cure. But AbbVie (NYSE:ABBV) is trialing a new drug which could be a game-changer. ABBV-552 is a unique anti-Alzheimer drug different from most currently on the market. |
22,170 | 2023-09-30 00:00:00 UTC | 3 Magnificent Dividend Stocks to Buy in October | ABBV | https://www.nasdaq.com/articles/3-magnificent-dividend-stocks-to-buy-in-october | null | null | There's no better time than October to invest in high-quality dividend stocks. That's because the new month offers a chance to get those dividend payments flowing sooner rather than later.
Three Motley Fool contributors believe they've identified magnificent dividend stocks to buy in October. Here's why they chose AbbV... | Attractive in multiple ways Keith Speights (AbbVie): Only 50 or so stocks can lay claim to increasing their dividend annually for 50 consecutive years or longer. AbbVie already has two worthy successors to Humira on the market -- Rinvoq and Skyrizi -- that are generating tremendous sales growth. Here's why they chose A... | Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). Attractive in multiple ways Keith Speights (AbbVie): Only 50 or so stocks can lay claim to increasing their dividend annually for 50 consecutive years or longer. AbbVie is one of them thanks to its impressive 5... | Attractive in multiple ways Keith Speights (AbbVie): Only 50 or so stocks can lay claim to increasing their dividend annually for 50 consecutive years or longer. Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). AbbVie is one of them thanks to its impressive 5... | There's also AbbVie's dividend yield of 3.9%. Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). Attractive in multiple ways Keith Speights (AbbVie): Only 50 or so stocks can lay claim to increasing their dividend annually for 50 consecutive years or longer. |
22,171 | 2023-09-29 00:00:00 UTC | Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-fda-and-ema-regulatory-updates-for-abbv-lly-sny-mrks-drugs | null | null | This week, the European Commission granted marketing approval to AbbVie’s ABBV Tepkinly (epcoritamab) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The FDA approved Lilly’s LLY diabetes drug, Jardiance (empagliflozin), for expanded use in chronic kidney disease (“CKD”).
The FDA also accep... | This week, the European Commission granted marketing approval to AbbVie’s ABBV Tepkinly (epcoritamab) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Recap of the Week’s Most Important Stories European Commission Approves AbbVie’s Epcoritamab: The European Commission granted conditional mar... | Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com cli... | Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com cli... | This week, the European Commission granted marketing approval to AbbVie’s ABBV Tepkinly (epcoritamab) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Recap of the Week’s Most Important Stories European Commission Approves AbbVie’s Epcoritamab: The European Commission granted conditional mar... |
22,172 | 2023-09-29 00:00:00 UTC | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-a-trending-stock%3A-facts-to-know-before-betting-on-it-9 | null | null | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this drugmaker have returned +3.6% over the past month versus the Zacks S&P 500 composite's -2.9% change. The Zacks ... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie be... | Last Reported Results and Surprise History AbbVie reported revenues of $13.87 billion in the last reported quarter, representing a year-over-year change of -4.9%. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost... | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 2.6% over this period. AbbVie is expected to post earnings of $2.87 per share for the current quarter, representing a year-over-year change of -21.6%. | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, h... |
22,173 | 2023-09-29 00:00:00 UTC | US judge refuses to block Medicare from negotiating drug prices | ABBV | https://www.nasdaq.com/articles/us-judge-refuses-to-block-medicare-from-negotiating-drug-prices | null | null | (Adds detail from the ruling in paragraphs 3-6)
By Brendan Pierson
Sept 29 (Reuters) - The U.S. government's Medicare health insurance program can begin negotiating prices for some prescription drugs this fall under a new program, a federal judge ruled on Friday, vindicating one of President Joe Biden's signature initi... | They include the blood thinners Eliquis from Bristol Myers Squibb and Pfizer , Xarelto from Johnson & Johnson , Merck & Co's diabetes drug Januvia, and AbbVie's leukemia treatment Imbruvica. The nation's largest business lobbying group has argued the program violates the U.S. Constitution by allowing the government to ... | They include the blood thinners Eliquis from Bristol Myers Squibb and Pfizer , Xarelto from Johnson & Johnson , Merck & Co's diabetes drug Januvia, and AbbVie's leukemia treatment Imbruvica. (Adds detail from the ruling in paragraphs 3-6) By Brendan Pierson Sept 29 (Reuters) - The U.S. government's Medicare health insu... | They include the blood thinners Eliquis from Bristol Myers Squibb and Pfizer , Xarelto from Johnson & Johnson , Merck & Co's diabetes drug Januvia, and AbbVie's leukemia treatment Imbruvica. (Adds detail from the ruling in paragraphs 3-6) By Brendan Pierson Sept 29 (Reuters) - The U.S. government's Medicare health insu... | They include the blood thinners Eliquis from Bristol Myers Squibb and Pfizer , Xarelto from Johnson & Johnson , Merck & Co's diabetes drug Januvia, and AbbVie's leukemia treatment Imbruvica. The order by U.S. District Judge Michael Newman in Dayton, Ohio, comes in a lawsuit brought against the Biden administration by t... |
22,174 | 2023-09-29 00:00:00 UTC | The Zacks Analyst Blog Highlights Oracle, AbbVie, Lowe's Companies, Ecolab and Motorola Solutions | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-oracle-abbvie-lowes-companies-ecolab-and-motorola | null | null | For Immediate Release
Chicago, IL – September 29, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Oracle Corp. ORCL, AbbVi... | Stocks recently featured in the blog include: Oracle Corp. ORCL, AbbVie Inc. ABBV, Lowe's Companies, Inc. LOW, Ecolab Inc. ECL and Motorola Solutions, Inc. MSI. Here are highlights from Thursday’s Analyst Blog: Top Analyst Reports for Oracle, AbbVie and Lowe's The Zacks Research Daily presents the best research output ... | Stocks recently featured in the blog include: Oracle Corp. ORCL, AbbVie Inc. ABBV, Lowe's Companies, Inc. LOW, Ecolab Inc. ECL and Motorola Solutions, Inc. MSI. Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp., AbbVie Inc. and Lowe's Companies, Inc. Click to get this free ... | Here are highlights from Thursday’s Analyst Blog: Top Analyst Reports for Oracle, AbbVie and Lowe's The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp., AbbVie Inc. and Lowe's Companies, Inc. Clic... | Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp., AbbVie Inc. and Lowe's Companies, Inc. Stocks recently featured in the blog include: Oracle Corp. ORCL, AbbVie Inc. ABBV, Lowe's Companies, Inc. LOW, Ecolab Inc. ECL and Motorola Solutions, Inc. MSI. Here are highlights fro... |
22,175 | 2023-09-29 00:00:00 UTC | AbbVie's blood cancer combo therapy fails in late-stage study | ABBV | https://www.nasdaq.com/articles/abbvies-blood-cancer-combo-therapy-fails-in-late-stage-study | null | null | Adds details throughout
Sept 29 (Reuters) - AbbVie ABBV.N said on Friday a late-stage study of its experimental combination therapy failed to show meaningful increase in the survival of patients with a form of blood cancer without the disease worsening.
The combination of AbbVie's Venclyxto and a steroid dexamethasone ... | Adds details throughout Sept 29 (Reuters) - AbbVie ABBV.N said on Friday a late-stage study of its experimental combination therapy failed to show meaningful increase in the survival of patients with a form of blood cancer without the disease worsening. The combination of AbbVie's Venclyxto and a steroid dexamethasone ... | Adds details throughout Sept 29 (Reuters) - AbbVie ABBV.N said on Friday a late-stage study of its experimental combination therapy failed to show meaningful increase in the survival of patients with a form of blood cancer without the disease worsening. The combination of AbbVie's Venclyxto and a steroid dexamethasone ... | Adds details throughout Sept 29 (Reuters) - AbbVie ABBV.N said on Friday a late-stage study of its experimental combination therapy failed to show meaningful increase in the survival of patients with a form of blood cancer without the disease worsening. The combination of AbbVie's Venclyxto and a steroid dexamethasone ... | Adds details throughout Sept 29 (Reuters) - AbbVie ABBV.N said on Friday a late-stage study of its experimental combination therapy failed to show meaningful increase in the survival of patients with a form of blood cancer without the disease worsening. The combination of AbbVie's Venclyxto and a steroid dexamethasone ... |
22,176 | 2023-09-29 00:00:00 UTC | Want $500 in Passive Income? Invest $3,500 Into These 3 Dividend Stocks and Wait 4 Years | ABBV | https://www.nasdaq.com/articles/want-%24500-in-passive-income-invest-%243500-into-these-3-dividend-stocks-and-wait-4-years | null | null | No return is guaranteed in the stock market. However, investors can have a high degree of certainty when it comes to dividend payments from quality companies.
Diamondback Energy (NASDAQ: FANG) offers a combination of a stable dividend and upside exposure to high energy prices. NextEra Energy Partners (NYSE: NEP) passes... | AbbVie (NYSE: ABBV) is a gigantic biopharma company that reduces the risks associated with the performance of a single drug by maintaining a diversified portfolio. A safer way to invest in big biopharma Daniel Foelber (AbbVie): AbbVie is one of the most powerful biopharma companies out there. But as long as the pipelin... | AbbVie (NYSE: ABBV) is a gigantic biopharma company that reduces the risks associated with the performance of a single drug by maintaining a diversified portfolio. A safer way to invest in big biopharma Daniel Foelber (AbbVie): AbbVie is one of the most powerful biopharma companies out there. But as long as the pipelin... | AbbVie (NYSE: ABBV) is a gigantic biopharma company that reduces the risks associated with the performance of a single drug by maintaining a diversified portfolio. A safer way to invest in big biopharma Daniel Foelber (AbbVie): AbbVie is one of the most powerful biopharma companies out there. But as long as the pipelin... | AbbVie's strong portfolio of products has led to growth in the stock price (up 77.8% in the last three years) and dividend growth. AbbVie (NYSE: ABBV) is a gigantic biopharma company that reduces the risks associated with the performance of a single drug by maintaining a diversified portfolio. A safer way to invest in ... |
22,177 | 2023-09-29 00:00:00 UTC | AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint | ABBV | https://www.nasdaq.com/articles/abbvie-says-phase-3-canova-trial-fails-to-meet-primary-endpoint | null | null | (RTTNews) - AbbVie (ABBV) announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments.
The data d... | (RTTNews) - AbbVie (ABBV) announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments. AbbVie wil... | (RTTNews) - AbbVie (ABBV) announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments. AbbVie wil... | (RTTNews) - AbbVie (ABBV) announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments. AbbVie wil... | (RTTNews) - AbbVie (ABBV) announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments. AbbVie wil... |
22,178 | 2023-09-29 00:00:00 UTC | Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-wisdomtree-u.s.-high-dividend-etf-dhs-a-strong-etf-right-now-8 | null | null | Designed to provide broad exposure to the Style Box - Large Cap Value category of the market, the WisdomTree U.S. High Dividend ETF (DHS) is a smart beta exchange traded fund launched on 06/16/2006.
What Are Smart Beta ETFs?
Products that are based on market cap weighted indexes, which are strategies designed to reflec... | Taking into account individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of the fund's total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Ex... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 100... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 100... | Taking into account individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of the fund's total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Ex... |
22,179 | 2023-09-28 00:00:00 UTC | Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views? | ABBV | https://www.nasdaq.com/articles/is-it-worth-investing-in-abbvie-abbv-based-on-wall-streets-bullish-views | null | null | When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Let's take a look at what these Wall Street heavyweights have ... | Let's take a look at what these Wall Street heavyweights have to say about AbbVie (ABBV) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. AbbVie currently has an average brokerage recommendation (ABR) of 1.97, on a scale of 1 to 5 (Strong Buy to Strong Sell), calcula... | AbbVie currently has an average brokerage recommendation (ABR) of 1.97, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) Let's take a look at what these Wall Street heavyweights have to say about AbbVie (ABBV) before we discuss the reliability of b... | AbbVie currently has an average brokerage recommendation (ABR) of 1.97, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) Let's take a look at what these Wall Street heavyweights have to say about AbbVie (ABBV) before we discuss the reliability of b... | Brokerage Recommendation Trends for ABBV Let's take a look at what these Wall Street heavyweights have to say about AbbVie (ABBV) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. AbbVie currently has an average brokerage recommendation (ABR) of 1.97, on a scale of 1 ... |
22,180 | 2023-09-26 00:00:00 UTC | Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher | ABBV | https://www.nasdaq.com/articles/dont-miss-the-boom%3A-3-biotech-stocks-set-to-explode-higher | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In the dynamic investment realm, one sector that continues to stand out is the area of biotech stocks. Though risky, especially when assessing established firms with market-ready drugs and vast research and development (R&D), the rewards can be significant.... | Coupled with the MHRA greenlight in the U.K. for its Crohn’s Disease medication, Rinvoq, and the FDA’s expanded approval for its migraine remedy, Qulpta, AbbVie’s global influence continues to flourish. Biotech Stocks to Buy: AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com In the fast-paced world of biotech... | Biotech Stocks to Buy: AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com In the fast-paced world of biotech, AbbVie (NYSE:ABBV) distinctly marks its territory as an undisputed leader. Moreover, AbbVie’s alliance with Genmab (NASDAQ:GMAB) has borne fruit, showcasing encouraging clinical outcomes for a follicul... | Biotech Stocks to Buy: AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com In the fast-paced world of biotech, AbbVie (NYSE:ABBV) distinctly marks its territory as an undisputed leader. Moreover, AbbVie’s alliance with Genmab (NASDAQ:GMAB) has borne fruit, showcasing encouraging clinical outcomes for a follicul... | Biotech Stocks to Buy: AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com In the fast-paced world of biotech, AbbVie (NYSE:ABBV) distinctly marks its territory as an undisputed leader. Moreover, AbbVie’s alliance with Genmab (NASDAQ:GMAB) has borne fruit, showcasing encouraging clinical outcomes for a follicul... |
22,181 | 2023-09-26 00:00:00 UTC | AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-epcoritamab-gets-approval-in-europe-for-dlbcl | null | null | AbbVie ABBV and partner Genmab GMAB announced that the European Commission has granted conditional marketing authorization to epcoritamab for treating relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). DLBCL is a common, aggressive and fast-growing form of non-Hodgkin's lymphoma (NHL).
Epcoritamab will... | AbbVie ABBV and partner Genmab GMAB announced that the European Commission has granted conditional marketing authorization to epcoritamab for treating relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Image Source: Zacks Investment Research Tepkinly is AbbVie's second hematological cancer drug to be a... | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report Aurinia Pharmaceuticals Inc (AUPH) : Free Stock Analysis Report Genmab A/S Sponsored ADR (GMAB) : Free Stock Analysis Report To read this article on Zacks.com click here. A... | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report Aurinia Pharmaceuticals Inc (AUPH) : Free Stock Analysis Report Genmab A/S Sponsored ADR (GMAB) : Free Stock Analysis Report To read this article on Zacks.com click here. A... | AbbVie ABBV and partner Genmab GMAB announced that the European Commission has granted conditional marketing authorization to epcoritamab for treating relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Year to date, AbbVie’s shares have lost 4.3% against the industry’s 5.7% rise. Image Source: Zacks In... |
22,182 | 2023-09-26 00:00:00 UTC | Clorox Pullback Presents a Chance to Clean Up on a 3.6% Dividend | ABBV | https://www.nasdaq.com/articles/clorox-pullback-presents-a-chance-to-clean-up-on-a-3.6-dividend | null | null | Since The Clorox Company (NYSE: CLX) rode a pandemic ‘clean freak’ wave to nearly $240 per share in August 2021, its market value has been bleached by over $13 billion.
The dirty truth? Clorox’s 44% two-year plunge has created an opportunity to own a defensive stock with a shiny dividend.
The consumer products mainsta... | MarketBeat’s robust stock screening tool reveals these top candidates: 1) ABBV - AbbVie has raised its dividend for 51 consecutive years and has a 3.9% forward yield. Since The Clorox Company (NYSE: CLX) rode a pandemic ‘clean freak’ wave to nearly $240 per share in August 2021, its market value has been bleached by ov... | MarketBeat’s robust stock screening tool reveals these top candidates: 1) ABBV - AbbVie has raised its dividend for 51 consecutive years and has a 3.9% forward yield. So why is the current stock price so low and the dividend yield so high? The company crushed the consensus earnings per share (EPS) estimate and posted 8... | MarketBeat’s robust stock screening tool reveals these top candidates: 1) ABBV - AbbVie has raised its dividend for 51 consecutive years and has a 3.9% forward yield. Clorox’s 44% two-year plunge has created an opportunity to own a defensive stock with a shiny dividend. Better yet, it is a dividend that is only likely ... | MarketBeat’s robust stock screening tool reveals these top candidates: 1) ABBV - AbbVie has raised its dividend for 51 consecutive years and has a 3.9% forward yield. So why is the current stock price so low and the dividend yield so high? Why Is Clorox Stock Down So Much? |
22,183 | 2023-09-25 00:00:00 UTC | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-outpaces-stock-market-gains%3A-what-you-should-know-6 | null | null | AbbVie (ABBV) closed the most recent trading day at $154.65, moving +1.25% from the previous trading session. This change outpaced the S&P 500's 0.4% gain on the day. Elsewhere, the Dow gained 0.13%, while the tech-heavy Nasdaq added 0.45%.
Coming into today, shares of the drugmaker had gained 4.12% in the past month. ... | AbbVie (ABBV) closed the most recent trading day at $154.65, moving +1.25% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. Any recent changes to analyst estimates for AbbVie should also be noted by investors. | AbbVie (ABBV) closed the most recent trading day at $154.65, moving +1.25% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. Any recent changes to analyst estimates for AbbVie should also be noted by investors. | AbbVie (ABBV) closed the most recent trading day at $154.65, moving +1.25% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. Any recent changes to analyst estimates for AbbVie should also be noted by investors. | AbbVie is currently a Zacks Rank #3 (Hold). AbbVie (ABBV) closed the most recent trading day at $154.65, moving +1.25% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. |
22,184 | 2023-09-25 00:00:00 UTC | AbbVie, Genmab: EU Approves TEPKINLY For Adults With R/R Diffuse Large B-cell Lymphoma | ABBV | https://www.nasdaq.com/articles/abbvie-genmab%3A-eu-approves-tepkinly-for-adults-with-r-r-diffuse-large-b-cell-lymphoma | null | null | (RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) announced Monday that the European Commission has granted conditional marketing authorization for TEPKINLY (epcoritamab) for adults with relapsed or refractory or R/R diffuse large B-cell lymphoma or DLBCL.
TEPKINLY is being co-developed by AbbVie and Genmab as part of th... | (RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) announced Monday that the European Commission has granted conditional marketing authorization for TEPKINLY (epcoritamab) for adults with relapsed or refractory or R/R diffuse large B-cell lymphoma or DLBCL. TEPKINLY is being co-developed by AbbVie and Genmab as part of th... | (RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) announced Monday that the European Commission has granted conditional marketing authorization for TEPKINLY (epcoritamab) for adults with relapsed or refractory or R/R diffuse large B-cell lymphoma or DLBCL. Roopal Thakkar, senior vice president, development and regulatory... | (RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) announced Monday that the European Commission has granted conditional marketing authorization for TEPKINLY (epcoritamab) for adults with relapsed or refractory or R/R diffuse large B-cell lymphoma or DLBCL. Roopal Thakkar, senior vice president, development and regulatory... | (RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) announced Monday that the European Commission has granted conditional marketing authorization for TEPKINLY (epcoritamab) for adults with relapsed or refractory or R/R diffuse large B-cell lymphoma or DLBCL. Under the oncology collaboration, the companies will share commer... |
22,185 | 2023-09-25 00:00:00 UTC | Argenx's 28% Surge & Promising Product Propel Investor Confidence | ABBV | https://www.nasdaq.com/articles/argenxs-28-surge-promising-product-propel-investor-confidence | null | null | If you want to get an isolated view of a constructive base taking shape in a strong stock, take a look at the Argenix SE (NASDAQ: ARGX) chart.
The stock gapped up nearly 28% on July 17, after announcing better-than-expected results from a clinical trial of its treatment for patients suffering from a progressive condit... | For example, its portfolio of autoimmune drugs could be an attractive addition for a large pharma company such as AbbVie Inc. (NYSE: ABBV), which is facing patent expirations in a few years. Analysts say many of AbbVie’s drugs will reach peak revenue potential around the time that AbbVie’s revenue stream is under press... | For example, its portfolio of autoimmune drugs could be an attractive addition for a large pharma company such as AbbVie Inc. (NYSE: ABBV), which is facing patent expirations in a few years. Analysts say many of AbbVie’s drugs will reach peak revenue potential around the time that AbbVie’s revenue stream is under press... | Healthcare stocks from the pharmaceutical and biotech industries that focus on antibody therapies include AbbVie, as well as Bristol-Myers Squibb Co. (NYSE: BMY), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), AstraZeneca PLC (NASDAQ: AZN), Amgen Inc. (NASDAQ: AMGN), AbCellera Biologics Inc. (NASDAQ: ABCL), Incyte Co... | For example, its portfolio of autoimmune drugs could be an attractive addition for a large pharma company such as AbbVie Inc. (NYSE: ABBV), which is facing patent expirations in a few years. Analysts say many of AbbVie’s drugs will reach peak revenue potential around the time that AbbVie’s revenue stream is under press... |
22,186 | 2023-09-22 00:00:00 UTC | Noteworthy ETF Outflows: IVW, ABBV, TMO, DHR | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-ivw-abbv-tmo-dhr | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $75.9 million dollar outflow -- that's a 0.2% decrease week over week (from 494,800,000 to 493,700,000). Among ... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.6%, and Danaher Corp (Symbol: DHR) is relatively unchanged. These ''units'' can be traded back and forth just like stocks, but can also be created or destr... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.6%, and Danaher Corp (Symbol: DHR) is relatively unchanged. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one ye... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.6%, and Danaher Corp (Symbol: DHR) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered a... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.6%, and Danaher Corp (Symbol: DHR) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered a... |
22,187 | 2023-09-21 00:00:00 UTC | 3 Bargain Stocks to Buy in a Market That's Priced for Perfection | ABBV | https://www.nasdaq.com/articles/3-bargain-stocks-to-buy-in-a-market-thats-priced-for-perfection | null | null | Stock valuations are at historically high levels. However, that doesn't mean you can't find stocks worth buying.
Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).
A... | Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). A new era for a longtime winner Keith Speights (AbbVie): AbbVie's shares currently trade at a forward earnings multiple of only 13.8. Why such a discounted valuation for AbbVie? | A new era for a longtime winner Keith Speights (AbbVie): AbbVie's shares currently trade at a forward earnings multiple of only 13.8. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). Why such a discounted valuation for AbbVie? | Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). A new era for a longtime winner Keith Speights (AbbVie): AbbVie's shares currently trade at a forward earnings multiple of only 13.8. Why such a discounted valuation for AbbVie? | Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). A new era for a longtime winner Keith Speights (AbbVie): AbbVie's shares currently trade at a forward earnings multiple of only 13.8. Why such a discounted valuation for AbbVie? |
22,188 | 2023-09-21 00:00:00 UTC | Interesting ABBV Put And Call Options For November 3rd | ABBV | https://www.nasdaq.com/articles/interesting-abbv-put-and-call-options-for-november-3rd | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the November 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new November 3rd contracts and identified one put and one call contract of particular interest.
The put c... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $155.00 strike highlighted in red: Considering the fact that the $155.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $152.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $155.00 strike price has a current bid of $2.99. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new November 3rd contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $155.00 strike highlighted in red: Consid... |
22,189 | 2023-09-21 00:00:00 UTC | Only 7 Large-Cap Dividend Kings Yield Over 3%. Here's My Top Pick to Buy Now. | ABBV | https://www.nasdaq.com/articles/only-7-large-cap-dividend-kings-yield-over-3.-heres-my-top-pick-to-buy-now. | null | null | If you're an income investor, you may have heard tales of mighty companies that have raised their payouts no matter the economic cycle. Only 49 companies over the past 50 years have managed to accomplish this monumental feat. But the ancient lore can be misleading as far fewer companies have a high yield and a market c... | Target (NYSE: TGT), Coca-Cola (NYSE: KO), Kimberly-Clark (NYSE: KMB), AbbVie (NYSE: ABBV), Altria (NYSE: MO), Stanley Black & Decker (NYSE: SWK), and 3M (NYSE: MMM) are the seven companies that stand alone on the throne of large-cap Dividend Kings with a yield over 3%. AbbVie is up there with Procter & Gamble and Coca-... | Target (NYSE: TGT), Coca-Cola (NYSE: KO), Kimberly-Clark (NYSE: KMB), AbbVie (NYSE: ABBV), Altria (NYSE: MO), Stanley Black & Decker (NYSE: SWK), and 3M (NYSE: MMM) are the seven companies that stand alone on the throne of large-cap Dividend Kings with a yield over 3%. AbbVie is up there with Procter & Gamble and Coca-... | Target (NYSE: TGT), Coca-Cola (NYSE: KO), Kimberly-Clark (NYSE: KMB), AbbVie (NYSE: ABBV), Altria (NYSE: MO), Stanley Black & Decker (NYSE: SWK), and 3M (NYSE: MMM) are the seven companies that stand alone on the throne of large-cap Dividend Kings with a yield over 3%. AbbVie is up there with Procter & Gamble and Coca-... | Target (NYSE: TGT), Coca-Cola (NYSE: KO), Kimberly-Clark (NYSE: KMB), AbbVie (NYSE: ABBV), Altria (NYSE: MO), Stanley Black & Decker (NYSE: SWK), and 3M (NYSE: MMM) are the seven companies that stand alone on the throne of large-cap Dividend Kings with a yield over 3%. AbbVie is up there with Procter & Gamble and Coca-... |
22,190 | 2023-09-20 00:00:00 UTC | Flee to Healthcare Stocks if Recession Rears its Head? | ABBV | https://www.nasdaq.com/articles/flee-to-healthcare-stocks-if-recession-rears-its-head | null | null | If you’re looking for a sector that’s on sale, look to healthcare. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.50% in the past month, lagging the S&P 500.
The top components within the sector are Eli Lilly & Co. (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), UnitedHealth Group Inc. (NYSE: UNH), Merc... | The top components within the sector are Eli Lilly & Co. (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), UnitedHealth Group Inc. (NYSE: UNH), Merck & Co. Inc. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV). The top-performing healthcare stock in the past three months is Eli Lilly, followed by Molina Healthcare Inc. (NYSE: MOH), ... | The top components within the sector are Eli Lilly & Co. (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), UnitedHealth Group Inc. (NYSE: UNH), Merck & Co. Inc. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV). The top-performing healthcare stock in the past three months is Eli Lilly, followed by Molina Healthcare Inc. (NYSE: MOH), ... | The top-performing healthcare stock in the past three months is Eli Lilly, followed by Molina Healthcare Inc. (NYSE: MOH), Amgen Inc. (NASDAQ: AMGN), Catalent Inc. (NYSE: CLT) and AbbVie. The top components within the sector are Eli Lilly & Co. (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), UnitedHealth Group Inc. (NYSE: ... | The top components within the sector are Eli Lilly & Co. (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), UnitedHealth Group Inc. (NYSE: UNH), Merck & Co. Inc. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV). The top-performing healthcare stock in the past three months is Eli Lilly, followed by Molina Healthcare Inc. (NYSE: MOH), ... |
22,191 | 2023-09-20 00:00:00 UTC | Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-wisdomtree-u.s.-high-dividend-etf-dhs-be-on-your-investing-radar-9 | null | null | The WisdomTree U.S. High Dividend ETF (DHS) was launched on 06/16/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Wisdomtree. It has amassed assets over $1.18 billion, making it one of the average siz... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 100... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... |
22,192 | 2023-09-19 00:00:00 UTC | The Top 7 Underrated Dividend Stocks Yielding 3% or More | ABBV | https://www.nasdaq.com/articles/the-top-7-underrated-dividend-stocks-yielding-3-or-more | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Looking for dividend stocks yielding 3% or more might seem pretty specific. Remember, though, the logic behind investing in underrated stocks is straightforward: Buy low and sell high in order to see a healthy return on your investment.
Making smart investm... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is a pharmaceutical stock that continues to face downward pressure that is undeserved. The evidence suggests that concerns were overblown and that AbbVie is adeptly filling the void. Humira is the anchor within AbbVie’s immunology portfolio and has ... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is a pharmaceutical stock that continues to face downward pressure that is undeserved. The evidence suggests that concerns were overblown and that AbbVie is adeptly filling the void. Humira is the anchor within AbbVie’s immunology portfolio and has ... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is a pharmaceutical stock that continues to face downward pressure that is undeserved. The evidence suggests that concerns were overblown and that AbbVie is adeptly filling the void. Humira is the anchor within AbbVie’s immunology portfolio and has ... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is a pharmaceutical stock that continues to face downward pressure that is undeserved. The evidence suggests that concerns were overblown and that AbbVie is adeptly filling the void. Humira is the anchor within AbbVie’s immunology portfolio and has ... |
22,193 | 2023-09-18 00:00:00 UTC | Should You Follow Warren Buffett's Lead and Sell HPQ Stock? | ABBV | https://www.nasdaq.com/articles/should-you-follow-warren-buffetts-lead-and-sell-hpq-stock | null | null | Berkshire Hathaway (BRK.B) - the conglomerate led by legendary value investor Warren Buffett - sold almost 5.5 million shares of HP (HPQ) last week. The announcement took the market by surprise, just as the initial news of Berkshire buying a stake in HP did last year.
Buffett has largely shied away from tech stocks - a... | Before HP, Berkshire has sold stakes in tech companies like Oracle (ORCL) and pharma names like Pfizer (PFE), AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Merck (MRK) quite quickly – and while a different investment manager at Berkshire might have made some of these decisions, Buffett himself certainly made the Oracl... | Before HP, Berkshire has sold stakes in tech companies like Oracle (ORCL) and pharma names like Pfizer (PFE), AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Merck (MRK) quite quickly – and while a different investment manager at Berkshire might have made some of these decisions, Buffett himself certainly made the Oracl... | Before HP, Berkshire has sold stakes in tech companies like Oracle (ORCL) and pharma names like Pfizer (PFE), AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Merck (MRK) quite quickly – and while a different investment manager at Berkshire might have made some of these decisions, Buffett himself certainly made the Oracl... | Before HP, Berkshire has sold stakes in tech companies like Oracle (ORCL) and pharma names like Pfizer (PFE), AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Merck (MRK) quite quickly – and while a different investment manager at Berkshire might have made some of these decisions, Buffett himself certainly made the Oracl... |
22,194 | 2023-09-18 00:00:00 UTC | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-outpaces-stock-market-gains%3A-what-you-should-know-5 | null | null | In the latest trading session, AbbVie (ABBV) closed at $153.94, marking a +1.2% move from the previous day. This change outpaced the S&P 500's 0.07% gain on the day. Meanwhile, the Dow gained 0.02%, and the Nasdaq, a tech-heavy index, added 0.01%.
Coming into today, shares of the drugmaker had gained 1.32% in the past ... | In the latest trading session, AbbVie (ABBV) closed at $153.94, marking a +1.2% move from the previous day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. In that report, analysts expect AbbVie to post earnings of $2.87 per share. | In the latest trading session, AbbVie (ABBV) closed at $153.94, marking a +1.2% move from the previous day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. In that report, analysts expect AbbVie to post earnings of $2.87 per share. | In the latest trading session, AbbVie (ABBV) closed at $153.94, marking a +1.2% move from the previous day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. In that report, analysts expect AbbVie to post earnings of $2.87 per share. | In the latest trading session, AbbVie (ABBV) closed at $153.94, marking a +1.2% move from the previous day. In that report, analysts expect AbbVie to post earnings of $2.87 per share. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. |
22,195 | 2023-09-18 00:00:00 UTC | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-attracting-investor-attention%3A-here-is-what-you-should-know-9 | null | null | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this drugmaker have returned +1.3%, compared to the Zacks S&P 500 composite's +0.4% change. During thi... | Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals indus... | For the next fiscal year, the consensus earnings estimate of $11.05 indicates a change of +0.4% from what AbbVie is expected to report a year ago. Last Reported Results and Surprise History AbbVie reported revenues of $13.87 billion in the last reported quarter, representing a year-over-year change of -4.9%. AbbVie (AB... | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has gained 0.2%. For the current quarter, AbbVie is expected to post earnings of $2.87 per share, indicating a change of -21.6% from the year-ago quart... | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has gained 0.2%. For the current quarter, AbbVie is expected to post earnings of $2.87 per share, indicating a change of -21.6% from the year-ago quart... |
22,196 | 2023-09-18 00:00:00 UTC | Allergan Aesthetics: Second Phase 3 Study With OnabotulinumtoxinA Meets Endpoints | ABBV | https://www.nasdaq.com/articles/allergan-aesthetics%3A-second-phase-3-study-with-onabotulinumtoxina-meets-endpoints | null | null | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), reported positive topline results from the second of three Phase 3 clinical studies evaluating onabotulinumtoxinA for the treatment of moderate to severe platysma prominence associated with platysma muscle activity. The company said all primary and secondary en... | "We are encouraged by these results, which demonstrated a significant reduction in the unwanted appearance of vertical band prominence on the neck and jawline," said Darin Messina, senior vice president, aesthetics R&D, AbbVie. (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), reported positive topline results... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), reported positive topline results from the second of three Phase 3 clinical studies evaluating onabotulinumtoxinA for the treatment of moderate to severe platysma prominence associated with platysma muscle activity. "We are encouraged by these results, which de... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), reported positive topline results from the second of three Phase 3 clinical studies evaluating onabotulinumtoxinA for the treatment of moderate to severe platysma prominence associated with platysma muscle activity. "We are encouraged by these results, which de... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), reported positive topline results from the second of three Phase 3 clinical studies evaluating onabotulinumtoxinA for the treatment of moderate to severe platysma prominence associated with platysma muscle activity. "We are encouraged by these results, which de... |
22,197 | 2023-09-17 00:00:00 UTC | Abbvie (ABBV) Declares $1.48 Dividend | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-declares-%241.48-dividend | null | null | Abbvie said on September 8, 2023 that its board of directors declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). Previously, the company paid $1.48 per share.
Shares must be purchased before the ex-div date of October 12, 2023 to qualify for the dividend. Shareholders of record as of October 13... | AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Guidance Including the Impact of Acquired IPR&D and Milestones Expense Form of AbbVie Inc. Performance-Vested Restricted Stock Unit Agreement* Fintel is one of the most... | Abbvie said on September 8, 2023 that its board of directors declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). There are 4348 funds or institutions reporting positions in Abbvie. Average portfolio weight of all funds dedicated to ABBV is 0.71%, a decrease of 15.57%. | Abbvie said on September 8, 2023 that its board of directors declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). There are 4348 funds or institutions reporting positions in Abbvie. Average portfolio weight of all funds dedicated to ABBV is 0.71%, a decrease of 15.57%. | Abbvie said on September 8, 2023 that its board of directors declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). There are 4348 funds or institutions reporting positions in Abbvie. Average portfolio weight of all funds dedicated to ABBV is 0.71%, a decrease of 15.57%. |
22,198 | 2023-09-15 00:00:00 UTC | US Chamber of Commerce urges judge to block Medicare drug pricing program | ABBV | https://www.nasdaq.com/articles/us-chamber-of-commerce-urges-judge-to-block-medicare-drug-pricing-program | null | null | By Nate Raymond
Sept 15 (Reuters) - A lawyer for the U.S. Chamber of Commerce on Friday urged a federal judge to block President Joe Biden's administration from implementing a new program that would let Medicare negotiate prices with pharmaceutical companies for selected costly drugs.
Jeffrey Bucholtz, the business gro... | Those drugs, announced on Aug. 29, include the blood thinners Eliquis from Bristol-Myers Squibb BMY.N and Pfizer PFE.N and Xarelto from Johnson & Johnson JNJ.N; Merck & Co's MRK.N diabetes drug Januvia; and AbbVie's ABBV.N leukemia treatment Imbruvica. Justice Department attorney Stephen Pezzi also argued the Chamber o... | While several other drugmakers including Chamber members have filed separate lawsuits challenging the program, Pezzi said AbbVie appeared to be litigating by "proxy." Those drugs, announced on Aug. 29, include the blood thinners Eliquis from Bristol-Myers Squibb BMY.N and Pfizer PFE.N and Xarelto from Johnson & Johnson... | Those drugs, announced on Aug. 29, include the blood thinners Eliquis from Bristol-Myers Squibb BMY.N and Pfizer PFE.N and Xarelto from Johnson & Johnson JNJ.N; Merck & Co's MRK.N diabetes drug Januvia; and AbbVie's ABBV.N leukemia treatment Imbruvica. Justice Department attorney Stephen Pezzi also argued the Chamber o... | Justice Department attorney Stephen Pezzi also argued the Chamber of Commerce and affiliates failed to establish standing to challenge the program as it identified just one member, AbbVie, that would be affected by it. Those drugs, announced on Aug. 29, include the blood thinners Eliquis from Bristol-Myers Squibb BMY.N... |
22,199 | 2023-09-15 00:00:00 UTC | Should SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-spdr-sp-dividend-etf-sdy-be-on-your-investing-radar-8 | null | null | If you're interested in broad exposure to the Large Cap Value segment of the US equity market, look no further than the SPDR S&P Dividend ETF (SDY), a passively managed exchange traded fund launched on 11/08/2005.
The fund is sponsored by State Street Global Advisors. It has amassed assets over $21.40 billion, making i... | Looking at individual holdings, 3m Co W/d (MMM) accounts for about 3% of total assets, followed by Intl Business Machines Corp (IBM) and Abbvie Inc (ABBV). Click to get this free report SPDR S&P Dividend ETF (SDY): ETF Research Reports International Business Machines Corporation (IBM) : Free Stock Analysis Report 3M Co... | Click to get this free report SPDR S&P Dividend ETF (SDY): ETF Research Reports International Business Machines Corporation (IBM) : Free Stock Analysis Report 3M Company (MMM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 1000... | Click to get this free report SPDR S&P Dividend ETF (SDY): ETF Research Reports International Business Machines Corporation (IBM) : Free Stock Analysis Report 3M Company (MMM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 1000... | Looking at individual holdings, 3m Co W/d (MMM) accounts for about 3% of total assets, followed by Intl Business Machines Corp (IBM) and Abbvie Inc (ABBV). Click to get this free report SPDR S&P Dividend ETF (SDY): ETF Research Reports International Business Machines Corporation (IBM) : Free Stock Analysis Report 3M Co... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.